JPWO2013051459A1 - Accelerator for promoting suppression of mRNA expression by RNA interference and use thereof - Google Patents
Accelerator for promoting suppression of mRNA expression by RNA interference and use thereof Download PDFInfo
- Publication number
- JPWO2013051459A1 JPWO2013051459A1 JP2013537478A JP2013537478A JPWO2013051459A1 JP WO2013051459 A1 JPWO2013051459 A1 JP WO2013051459A1 JP 2013537478 A JP2013537478 A JP 2013537478A JP 2013537478 A JP2013537478 A JP 2013537478A JP WO2013051459 A1 JPWO2013051459 A1 JP WO2013051459A1
- Authority
- JP
- Japan
- Prior art keywords
- group
- expression
- resveratrol
- nucleic acid
- rna interference
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 title claims abstract description 43
- 230000009368 gene silencing by RNA Effects 0.000 title claims abstract description 43
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 38
- 230000001737 promoting effect Effects 0.000 title claims description 7
- 230000001629 suppression Effects 0.000 title abstract description 10
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 124
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 113
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 113
- 229940016667 resveratrol Drugs 0.000 claims abstract description 113
- 108091070501 miRNA Proteins 0.000 claims abstract description 58
- 239000002679 microRNA Substances 0.000 claims abstract description 58
- 101150084233 ago2 gene Proteins 0.000 claims abstract description 54
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 44
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 44
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 44
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 238000013518 transcription Methods 0.000 claims abstract description 23
- 230000035897 transcription Effects 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 101710099377 Protein argonaute 2 Proteins 0.000 claims abstract description 13
- 102100034207 Protein argonaute-2 Human genes 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 81
- 201000011510 cancer Diseases 0.000 claims description 68
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 claims description 40
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 claims description 39
- 239000000126 substance Substances 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 16
- -1 o-methoxyphenyl group Chemical group 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 11
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 125000001165 hydrophobic group Chemical group 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 239000008177 pharmaceutical agent Substances 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- 125000005120 alkyl cycloalkyl alkyl group Chemical group 0.000 claims description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 2
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 125000005561 phenanthryl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000001725 pyrenyl group Chemical group 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
- 235000013373 food additive Nutrition 0.000 abstract description 7
- 239000002778 food additive Substances 0.000 abstract description 7
- 238000004458 analytical method Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 127
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- 230000000694 effects Effects 0.000 description 24
- 108091027766 Mir-143 Proteins 0.000 description 19
- 230000009545 invasion Effects 0.000 description 16
- 108091058688 miR-141 stem-loop Proteins 0.000 description 15
- 230000003833 cell viability Effects 0.000 description 12
- 108091074450 miR-200c stem-loop Proteins 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 10
- 229960003668 docetaxel Drugs 0.000 description 10
- 108091027943 miR-16 stem-loop Proteins 0.000 description 10
- 230000010261 cell growth Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000021375 Xenogenes Species 0.000 description 7
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 238000004020 luminiscence type Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 102100032912 CD44 antigen Human genes 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 4
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 3
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 3
- 101000763328 Homo sapiens RISC-loading complex subunit TARBP2 Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102100026965 RISC-loading complex subunit TARBP2 Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003161 ribonuclease inhibitor Substances 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101000869796 Homo sapiens Microprocessor complex subunit DGCR8 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100032459 Microprocessor complex subunit DGCR8 Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 240000000851 Vaccinium corymbosum Species 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 2
- 229960002050 hydrofluoric acid Drugs 0.000 description 2
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Chemical compound Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 125000005270 trialkylamine group Chemical group 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- PYIXHKGTJKCVBJ-UHFFFAOYSA-N Astraciceran Natural products C1OC2=CC(O)=CC=C2CC1C1=CC(OCO2)=C2C=C1OC PYIXHKGTJKCVBJ-UHFFFAOYSA-N 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- NDVRQFZUJRMKKP-UHFFFAOYSA-N Betavulgarin Natural products O=C1C=2C(OC)=C3OCOC3=CC=2OC=C1C1=CC=CC=C1O NDVRQFZUJRMKKP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 241001199075 Dichelostemma capitatum Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- IHPVFYLOGNNZLA-UHFFFAOYSA-N Phytoalexin Natural products COC1=CC=CC=C1C1OC(C=C2C(OCO2)=C2OC)=C2C(=O)C1 IHPVFYLOGNNZLA-UHFFFAOYSA-N 0.000 description 1
- 244000292697 Polygonum aviculare Species 0.000 description 1
- 235000006386 Polygonum aviculare Nutrition 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 244000217456 Vaccinium stamineum Species 0.000 description 1
- 235000018820 Vaccinium stamineum Nutrition 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 229940005991 chloric acid Drugs 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- 229940077239 chlorous acid Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- VMUWIFNDNXXSQA-UHFFFAOYSA-N hypofluorite Chemical compound F[O-] VMUWIFNDNXXSQA-UHFFFAOYSA-N 0.000 description 1
- GEOVEUCEIQCBKH-UHFFFAOYSA-N hypoiodous acid Chemical compound IO GEOVEUCEIQCBKH-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000003253 miRNA assay Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XTAZYLNFDRKIHJ-UHFFFAOYSA-N n,n-dioctyloctan-1-amine Chemical compound CCCCCCCCN(CCCCCCCC)CCCCCCCC XTAZYLNFDRKIHJ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- LLYCMZGLHLKPPU-UHFFFAOYSA-N perbromic acid Chemical compound OBr(=O)(=O)=O LLYCMZGLHLKPPU-UHFFFAOYSA-N 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000280 phytoalexin Substances 0.000 description 1
- 150000001857 phytoalexin derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 235000021013 raspberries Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- LUKBXSAWLPMMSZ-UHFFFAOYSA-N resveratrol Chemical compound C1=CC(O)=CC=C1C=CC1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000008275 solid aerosol Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- CHYBTAZWINMGHA-UHFFFAOYSA-N tetraoctylazanium Chemical compound CCCCCCCC[N+](CCCCCCCC)(CCCCCCCC)CCCCCCCC CHYBTAZWINMGHA-UHFFFAOYSA-N 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ABDKAPXRBAPSQN-UHFFFAOYSA-N veratrole Chemical compound COC1=CC=CC=C1OC ABDKAPXRBAPSQN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Abstract
RNA干渉によるmRNA発現の抑制を促進する促進剤を提供する。本発明の促進剤は、レスベラトロール(resveratrol)、レスベラトロール誘導体、それらの互変異性体、幾何異性体および立体異性体、ならびにそれらの塩からなる群から選択される少なくとも一つの有効成分を含み、前記有効成分が、RNA干渉によりmRNAの発現を抑制する核酸の転写、およびArgonaute2(Ago2)の発現の少なくとも一方を促進することを特徴とする。前記核酸は、miRNAが好ましい。本発明の促進剤は、例えば、RNA干渉を利用した疾患の治療方法、医薬品、食品添加物、ノックダウンによる遺伝子解析等に適用できる。Provided is a promoter that promotes suppression of mRNA expression due to RNA interference. The accelerator of the present invention is at least one active ingredient selected from the group consisting of resveratrol, resveratrol derivatives, tautomers, geometric isomers and stereoisomers thereof, and salts thereof The active ingredient promotes at least one of transcription of a nucleic acid that suppresses mRNA expression by RNA interference and expression of Argonaute2 (Ago2). The nucleic acid is preferably miRNA. The promoter of the present invention can be applied to, for example, a disease treatment method using RNA interference, a pharmaceutical, a food additive, gene analysis by knockdown, and the like.
Description
本発明は、RNA干渉によるmRNA発現の抑制を促進する促進剤およびその用途に関する。 The present invention relates to a promoter for promoting suppression of mRNA expression due to RNA interference and use thereof.
RNA干渉(RNAi)は、miRNA(micro RNA)、またはsiRNA(small interfering RNA)等の核酸が、前記核酸に相補的な標的mRNAを特異的に分解することにより、標的タンパク質の発現を特異的に抑制する現象である。このような現象は、細胞の分化、増殖、アポトーシス等の生命現象に関わっていると考えられている。このため、前記核酸は、種々の疾患の診断法または治療薬としての応用が期待され、その実用化に向けて、様々な研究が進められている。 In RNA interference (RNAi), nucleic acid such as miRNA (micro RNA) or siRNA (small interfering RNA) specifically degrades target mRNA complementary to the nucleic acid, thereby specifically expressing the expression of the target protein. It is a phenomenon to suppress. Such a phenomenon is considered to be related to life phenomena such as cell differentiation, proliferation, and apoptosis. For this reason, the nucleic acid is expected to be applied as a diagnostic method or therapeutic agent for various diseases, and various researches are being promoted for its practical use.
miRNAの医薬品への応用としては、例えば、線維症関連疾患の治療に、特定のmiRNAを投与することが提案されている(例えば、特許文献1参照)。 As an application of miRNA to pharmaceuticals, for example, it has been proposed to administer a specific miRNA for the treatment of fibrosis-related diseases (for example, see Patent Document 1).
前記特許文献1のように、miRNAを医薬品として応用する研究は盛んに行われている。しかしながら、例えば、内在性のmiRNAおよび投与された外因性のmiRNAによるmRNA発現の抑制を促進する促進剤の開発は行われておらず、このような促進剤はこれまで存在しなかった。また、miRNAに限らず、他の核酸によるmRNA発現の抑制を促進する促進剤は存在しなかった。 As described in Patent Document 1, research on applying miRNA as a pharmaceutical has been actively conducted. However, for example, an accelerator that promotes suppression of mRNA expression by endogenous miRNA and administered exogenous miRNA has not been developed, and such an accelerator has not existed so far. Moreover, there is no promoter that promotes suppression of mRNA expression by other nucleic acids, not limited to miRNA.
そこで、本発明は、RNA干渉によるmRNA発現の抑制を促進する促進剤を提供することを目的とする。 Then, an object of this invention is to provide the promoter which accelerates | stimulates suppression of the mRNA expression by RNA interference.
本発明の促進剤は、レスベラトロール(resveratrol)、レスベラトロール誘導体、それらの互変異性体、幾何異性体および立体異性体、ならびにそれらの塩からなる群から選択される少なくとも一つの有効成分を含み、前記有効成分が、RNA干渉によりmRNAの発現を抑制する核酸の転写、およびArgonaute2(Ago2)の発現の少なくとも一方を促進することを特徴とする。 The accelerator of the present invention is at least one active ingredient selected from the group consisting of resveratrol, resveratrol derivatives, tautomers, geometric isomers and stereoisomers thereof, and salts thereof The active ingredient promotes at least one of transcription of a nucleic acid that suppresses mRNA expression by RNA interference and expression of Argonaute2 (Ago2).
本発明者は、レスベラトロール(resveratrol)、レスベラトロール誘導体、それらの互変異性体、幾何異性体および立体異性体、ならびにそれらの塩からなる群から選択される少なくとも一つの有効成分が、miRNA等の核酸の転写を活性化すること、およびRNAi経路において、前記核酸に結合し、標的mRNAの認識・切断を行うRISC(RNA-induced silencing complex)の主要なコンポーネントの一つであるArgonaute2(Ago2)の発現を誘導することにより、RNA干渉によるmRNA発現の抑制が促進されることを突き止め、本発明に到達した。本発明の促進剤によれば、RNA干渉によるmRNA発現の抑制を促進できる。 The inventor has at least one active ingredient selected from the group consisting of resveratrol, resveratrol derivatives, tautomers, geometric isomers and stereoisomers thereof, and salts thereof. Argonaute2 (one of the main components of RISC (RNA-induced silencing complex) that activates transcription of nucleic acids such as miRNA and binds to the nucleic acid and recognizes and cleaves the target mRNA in the RNAi pathway ( By inducing the expression of Ago2), it was found that suppression of mRNA expression by RNA interference was promoted, and the present invention was reached. According to the promoter of the present invention, suppression of mRNA expression due to RNA interference can be promoted.
(促進剤)
本発明の促進剤は、前述のように、レスベラトロール(resveratrol)、レスベラトロール誘導体、それらの互変異性体、幾何異性体および立体異性体、ならびにそれらの塩からなる群から選択される少なくとも一つの有効成分を含み、前記有効成分が、RNA干渉によりmRNAの発現を抑制する核酸の転写、およびArgonaute2(Ago2)の発現の少なくとも一方を促進することを特徴とする。本発明の促進剤は、例えば、in vitroで細胞に添加してもよいし、in vivoで個体動物に投与してもよい。また、本発明の促進剤により転写が促進される核酸は、例えば、細胞における内因性の核酸でもよいし、細胞外から投与された外因性の核酸でもよい。例えば、本発明の促進剤により前記内因性の核酸の転写が促進されることで、前記内因性の核酸によるRNA干渉作用が促進され、例えば、疾患に関与する特定の遺伝子のmRNAの発現を抑制でき、その結果、前記疾患を治療できる。さらに、本発明の促進剤により前記外因性の核酸の転写が促進されることで、前記外因性の核酸によるRNA干渉作用が促進され、例えば、さらに、疾患に関与する特定の遺伝子のmRNAの発現を抑制でき、その結果、より効果的に前記疾患を治療することもできる。(Accelerator)
The promoter of the present invention is selected from the group consisting of resveratrol, resveratrol derivatives, tautomers, geometric isomers and stereoisomers thereof, and salts thereof as described above. It contains at least one active ingredient, and the active ingredient promotes at least one of transcription of a nucleic acid that suppresses mRNA expression by RNA interference and expression of Argonaute2 (Ago2). The promoter of the present invention may be added to cells, for example, in vitro , or may be administered to an individual animal in vivo . In addition, the nucleic acid whose transcription is promoted by the promoter of the present invention may be, for example, an endogenous nucleic acid in a cell or an exogenous nucleic acid administered from outside the cell. For example, by promoting the transcription of the endogenous nucleic acid by the promoter of the present invention, the RNA interference action by the endogenous nucleic acid is promoted, for example, the expression of mRNA of a specific gene involved in a disease is suppressed. As a result, the disease can be treated. Furthermore, the promoter of the present invention promotes the transcription of the exogenous nucleic acid, whereby the RNA interference action by the exogenous nucleic acid is promoted. For example, the expression of mRNA of a specific gene involved in the disease As a result, the disease can be treated more effectively.
本発明の促進剤において、前記レスベラトロールおよびレスベラトロール誘導体が、下記化学式(1)で表される化合物であることが好ましい。
前記化学式(1)中、R1、R2およびR3は、それぞれ、水素原子または疎水基であり、互いに同一でも異なっていてもよい。例えば、R1、R2およびR3の2つまたは3つが疎水基である場合、それらは、互いに同一の疎水基でもよいし、異なる疎水基でもよい。R1、R2およびR3の少なくとも一つが疎水基であると、例えば、前記化学式(1)で表される化合物の親水性が抑制されることにより、前記有効成分が生体組織内に留まりやすい。前記有効成分が生体組織内に留まりやすければ、RNA干渉によりmRNAの発現を抑制する核酸の転写、およびArgonaute2(Ago2)の発現の少なくとも一方を促進するという効果を、さらに発揮しやすい。In the chemical formula (1), R 1 , R 2 and R 3 are each a hydrogen atom or a hydrophobic group, and may be the same or different from each other. For example, when two or three of R 1 , R 2 and R 3 are hydrophobic groups, they may be the same or different hydrophobic groups. When at least one of R 1 , R 2 and R 3 is a hydrophobic group, for example, the hydrophilicity of the compound represented by the chemical formula (1) is suppressed, so that the active ingredient tends to stay in the living tissue. . If the active ingredient is likely to remain in the living tissue, the effect of accelerating at least one of transcription of nucleic acid that suppresses mRNA expression by RNA interference and expression of Argonaute2 (Ago2) can be more easily exhibited.
前記化学式(1)中、R1、R2およびR3における前記疎水基が、それぞれ、飽和または不飽和炭化水素基であることがより好ましい。前記飽和または不飽和炭化水素基は、分枝構造を含んでいても含んでいなくてもよく、環状構造を含んでいても含んでいなくてもよい。前記飽和炭化水素基の炭素数は、特に限定されないが、例えば1〜30、好ましくは1〜20、より好ましくは1〜10である。前記不飽和炭化水素基の炭素数は、特に限定されないが、例えば2〜30、好ましくは2〜20、より好ましくは2〜10である。また、前記飽和または不飽和炭化水素基は、さらに、1または複数のアルコキシ基またはアリールオキシ基で置換されていても置換されていなくてもよい。前記アルコキシ基の炭素数は、特に限定されないが、例えば1〜30、好ましくは1〜20、より好ましくは1〜10である。前記アリールオキシ基の炭素数は、特に限定されないが、例えば5〜30、好ましくは5〜20、より好ましくは6〜10である。なお、本発明において、前記「アルコキシ基」は、オキシ基(酸素原子、−O−)に、アリール基(芳香族炭化水素基)以外の任意の炭化水素基が結合した基をいう。前記「アリール基(芳香族炭化水素基)以外の任意の炭化水素基」は、前記オキシ基にアリール基(芳香族炭化水素基)が直接結合していなければ、その構造中にアリール基を含む基(例えば、ベンジル基等)であってもよい。また、本発明において、前記「アリールオキシ基」は、オキシ基(酸素原子、−O−)に、アリール基(芳香族炭化水素基)が直接結合した基をいう。前記「アリール基(芳香族炭化水素基)」は、前記オキシ基に芳香環が直接結合していれば、その構造中に、脂肪族炭化水素により形成された置換基、連結基等を含んでいてもよい。前記脂肪族炭化水素により形成された置換基は、例えば、アルキル基、アルケニル基、アルキニル基等があげられる。前記脂肪族炭化水素により形成された連結基は、例えば、アルキレン基、アルケニレン基、アルキニレン基等があげられる。In the chemical formula (1), the hydrophobic groups in R 1 , R 2 and R 3 are more preferably saturated or unsaturated hydrocarbon groups, respectively. The saturated or unsaturated hydrocarbon group may or may not contain a branched structure, and may or may not contain a cyclic structure. Although carbon number of the said saturated hydrocarbon group is not specifically limited, For example, it is 1-30, Preferably it is 1-20, More preferably, it is 1-10. Although carbon number of the said unsaturated hydrocarbon group is not specifically limited, For example, 2-30, Preferably it is 2-20, More preferably, it is 2-10. The saturated or unsaturated hydrocarbon group may be further substituted or unsubstituted with one or more alkoxy groups or aryloxy groups. Although carbon number of the said alkoxy group is not specifically limited, For example, it is 1-30, Preferably it is 1-20, More preferably, it is 1-10. Although carbon number of the said aryloxy group is not specifically limited, For example, 5-30, Preferably it is 5-20, More preferably, it is 6-10. In the present invention, the “alkoxy group” refers to a group in which any hydrocarbon group other than an aryl group (aromatic hydrocarbon group) is bonded to an oxy group (oxygen atom, —O—). The “arbitrary hydrocarbon group other than the aryl group (aromatic hydrocarbon group)” includes an aryl group in its structure unless the aryl group (aromatic hydrocarbon group) is directly bonded to the oxy group. It may be a group (for example, a benzyl group). In the present invention, the “aryloxy group” refers to a group in which an aryl group (aromatic hydrocarbon group) is directly bonded to an oxy group (oxygen atom, —O—). The “aryl group (aromatic hydrocarbon group)” includes a substituent formed by an aliphatic hydrocarbon, a linking group, or the like in the structure if an aromatic ring is directly bonded to the oxy group. May be. Examples of the substituent formed by the aliphatic hydrocarbon include an alkyl group, an alkenyl group, and an alkynyl group. Examples of the linking group formed from the aliphatic hydrocarbon include an alkylene group, an alkenylene group, and an alkynylene group.
なお、本発明において「アリール基」は、芳香族炭化水素基をいい、例えば、単環でも縮合環でもよく、ビフェニリル基(C6H5−C6H4−)等でもよい。本発明において、アリール基(芳香族炭化水素基)の炭素数は、特に限定されないが、例えば5〜30、好ましくは5〜20、より好ましくは6〜10である。アリール基をその構造中に含む置換基、またはアリール基から誘導される基(例えば、アリールオキシ基、アラルキル基等)においても同様である。また、本発明において「アルキル基」は、具体的には、例えば、メチル基、エチル基、n-プロピル基、イソプロピル基、n-ブチル基、イソブチル基、sec-ブチル基およびtert-ブチル基、ペンチル基、ヘキシル基、ヘプチル基、オクチル基、ノニル基、デシル基、ウンデシル基、ドデシル基、トリデシル基、テトラデシル基、ペンタデシル基、ヘキサデシル基、ヘプタデシル基、オクタデシル基、ノナデシル基、イコシル基等が挙げられる。アルキル基をその構造中に含む基またはアルキル基から誘導される基(例えば、アルキルオキシ基、アルキレン基、アラルキル基等)においても同様である。本発明において、「アルケニル基」は、例えば、前記アルキル基の炭素−炭素単結合の1または複数が二重結合に置き換わった基でもよい。「アルキニル基」は、例えば、前記アルキル基の炭素−炭素単結合の1または複数が三重結合に置き換わった基でもよい。アルケニル基もしくはアルキニル基をその構造中に含む基、または、アルケニル基もしくはアルキニル基から誘導される基においても同様である。また、本発明において、置換基等に異性体が存在する場合は、特に限定しない限り、どの異性体でもよい。例えば、単に「プロピル基」という場合は、n-プロピル基でもイソプロピル基でもよい。また、例えば、単に「ビフェニリル基」という場合は、2−ビフェニリル基でも、3−ビフェニリル基でも、4−ビフェニリル基でもよい。In the present invention, the “aryl group” refers to an aromatic hydrocarbon group, and may be, for example, a single ring or a condensed ring, or a biphenylyl group (C 6 H 5 -C 6 H 4 —). In the present invention, the number of carbon atoms of the aryl group (aromatic hydrocarbon group) is not particularly limited, but is, for example, 5 to 30, preferably 5 to 20, and more preferably 6 to 10. The same applies to a substituent containing an aryl group in the structure or a group derived from an aryl group (for example, an aryloxy group, an aralkyl group, etc.). In the present invention, the “alkyl group” specifically includes, for example, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, and a tert-butyl group, Examples include pentyl group, hexyl group, heptyl group, octyl group, nonyl group, decyl group, undecyl group, dodecyl group, tridecyl group, tetradecyl group, pentadecyl group, hexadecyl group, heptadecyl group, octadecyl group, nonadecyl group, icosyl group, etc. It is done. The same applies to a group containing an alkyl group in its structure or a group derived from an alkyl group (for example, an alkyloxy group, an alkylene group, an aralkyl group, etc.). In the present invention, the “alkenyl group” may be, for example, a group in which one or more carbon-carbon single bonds of the alkyl group are replaced with double bonds. The “alkynyl group” may be, for example, a group in which one or more carbon-carbon single bonds of the alkyl group are replaced with triple bonds. The same applies to a group containing an alkenyl group or an alkynyl group in its structure, or a group derived from an alkenyl group or an alkynyl group. In the present invention, when an isomer is present in a substituent or the like, any isomer may be used unless specifically limited. For example, when simply referring to “propyl group”, it may be an n-propyl group or an isopropyl group. Further, for example, when simply referred to as “biphenylyl group”, it may be a 2-biphenylyl group, a 3-biphenylyl group, or a 4-biphenylyl group.
前記化学式(1)中のR1、R2およびR3における前記疎水基の、前記飽和炭化水素基は、直鎖もしくは分枝アルキル基、シクロアルキル基、アルキルシクロアルキル基、シクロアルキルアルキル基、またはアルキルシクロアルキルアルキル基であることがさらに好ましく、炭素数1〜6の直鎖または分枝アルキル基であることがさらに好ましい。また、前記化学式(1)中のR1、R2およびR3における前記疎水基の、前記不飽和炭化水素基は、アルケニル基、アルキニル基、アリール基、またはアラルキル基であることがさらに好ましい。前記アリール基およびアラルキル基の芳香環の各水素原子は、それぞれ、飽和もしくは不飽和炭化水素基、アルコキシ基、またはアリールオキシ基で置換されていてもよい。前記アリール基は、シクロペンタジエニル基、フェニル基、o−トリル基、m−トリル基、p−トリル基、o−メトキシフェニル基、m−メトキシフェニル基、p−メトキシフェニル基、1−ナフチル基、2−ナフチル基、ビフェニリル基、アントリル基、フェナントリル基、またはピレニル基であることがさらに好ましい。なお、シクロペンタジエニル基は、アニオン状態では、π電子数が6となり、芳香族性を示す。The saturated hydrocarbon group of the hydrophobic group in R 1 , R 2 and R 3 in the chemical formula (1) is a linear or branched alkyl group, a cycloalkyl group, an alkylcycloalkyl group, a cycloalkylalkyl group, Alternatively, an alkylcycloalkylalkyl group is more preferable, and a linear or branched alkyl group having 1 to 6 carbon atoms is more preferable. The unsaturated hydrocarbon group of the hydrophobic group in R 1 , R 2 and R 3 in the chemical formula (1) is more preferably an alkenyl group, an alkynyl group, an aryl group, or an aralkyl group. Each hydrogen atom of the aromatic ring of the aryl group and aralkyl group may be substituted with a saturated or unsaturated hydrocarbon group, an alkoxy group, or an aryloxy group. The aryl group includes cyclopentadienyl group, phenyl group, o-tolyl group, m-tolyl group, p-tolyl group, o-methoxyphenyl group, m-methoxyphenyl group, p-methoxyphenyl group, 1-naphthyl. More preferably, it is a group, 2-naphthyl group, biphenylyl group, anthryl group, phenanthryl group, or pyrenyl group. Note that the cyclopentadienyl group has an π-electron number of 6 in an anionic state and exhibits aromaticity.
前記化学式(1)で表される化合物は、下記化学式(2)で表されるレスベラトロール(resveratrol)および下記化学式(3)で表されるプテロスチルベン(pterostilbene)の少なくとも一つであることが特に好ましい。なお、下記化学式(2)で表されるレスベラトロールは、前記化学式(1)において、R1、R2およびR3が全て水素原子である化合物である。また、下記化学式(3)で表されるプテロスチルベンは、前記化学式(1)において、R1が水素原子であり、R2およびR3がメチル基である化合物である。
前記レスベラトロールは、ブドウ(ブドウ科ブドウ、Vitis vinifera)の果実のファイトアレキシンとして見出された物質である。前記レスベラトロールは、例えば、天然物由来のものでもよいし、人工合成されたものでもよい。前記レスベラトロールが天然由来の場合、その由来は、特に限定されない。例えば、レスベラトロールは、ブドウの果実に加え、木の実(例えば、ラズベリー、ブルーベリー、メリンジョ等)、草の実(例えば、ピーナッツ等)、およびその他の植物(例えば、イタドリ等)等、多くの種類の植物に含まれている。前記レスベラトロールは、例えば、これらの植物の一種または二種以上から抽出したものでもよい。また、前記レスベラトロールが天然物由来のものである場合、前記レスベラトロールは、例えば、精製されていないクルードな状態のものでもよいし、精製された状態のもの(精製品)でもよい。また、前記レスベラトロールは、例えば、前述のように、その誘導体でもよい。前記レスベラトロールの誘導体としては、例えば、前記化学式(1)で表される化合物(前記化学式(2)で表されるレスベラトロール自体を除く)でもよい。また、例えば、前記化学式(3)で表されるプテロスチルベンは、前記レスベラトロールの類似体(アナログ)であり、前記レスベラトロールの誘導体に含まれる。前記レスベラトロールは、例えば、市販品を購入してもよいし、前記天然物から従来公知の方法で自家調製してよい。The resveratrol is a substance found as a phytoalexin in the fruit of grapes ( Vitis vinifera ). The resveratrol may be derived from a natural product or may be artificially synthesized, for example. When the resveratrol is naturally derived, its origin is not particularly limited. For example, resveratrol has many varieties, including grape fruits, nuts (eg, raspberries, blueberries, meringo), grass nuts (eg, peanuts), and other plants (eg, knotweed). Contained in plants. The resveratrol may be extracted from one or more of these plants, for example. Further, when the resveratrol is derived from a natural product, the resveratrol may be in a crude state that is not purified, or may be in a purified state (purified product). Further, the resveratrol may be a derivative thereof as described above, for example. The derivative of resveratrol may be, for example, a compound represented by the chemical formula (1) (excluding resveratrol itself represented by the chemical formula (2)). Further, for example, pterostilbene represented by the chemical formula (3) is an analog (analog) of the resveratrol, and is included in the resveratrol derivative. The resveratrol may be commercially available, for example, or may be self-prepared from the natural product by a conventionally known method.
前記プテロスチルベンは、前述のように、前記レスベラトロールの類似体(アナログ)である。前記プテロスチルベンは、例えば、天然物由来のものでもよいし、人工合成されたものでもよい。前記プテロスチルベンが天然由来の場合、その由来は、特に限定されない。例えば、プテロスチルベンは、ブルーベリーのうち、特定の品種(例えば、ディアベリー)に多く含まれる。前記プテロスチルベンは、例えば、前記ディアベリー等から抽出したものでもよい。また、前記プテロスチルベンが天然物由来のものである場合、前記プテロスチルベンは、例えば、精製されていないクルードな状態のものでもよいし、精製された状態のもの(精製品)でもよい。また、前記プテロスチルベンは、例えば、その誘導体でもよい。前記プテロスチルベンの誘導体としては、例えば、前記化学式(1)で表される化合物(前記化学式(3)で表されるプテロスチルベン自体を除く)でもよい。前記プテロスチルベンは、例えば、市販品を購入してもよいし、前記天然物から従来公知の方法で自家調製してよい。 The pterostilbene is an analog (analog) of the resveratrol as described above. The pterostilbene may be derived from natural products or artificially synthesized, for example. When the pterostilbene is naturally derived, its origin is not particularly limited. For example, pterostilbene is abundant in certain varieties (for example, deerberry) among blueberries. The pterostilbene may be extracted from, for example, the diaberry. When the pterostilbene is derived from a natural product, the pterostilbene may be, for example, a crude state that has not been purified, or a purified state (purified product). The pterostilbene may be a derivative thereof, for example. The pterostilbene derivative may be, for example, a compound represented by the chemical formula (1) (excluding pterostilbene itself represented by the chemical formula (3)). The pterostilbene may be purchased, for example, as a commercially available product, or may be self-prepared from the natural product by a conventionally known method.
なお、前述のように、前記化学式(1)で表される化合物に互変異性体、幾何異性体または立体異性体(例えば、配座異性体、光学異性体等)等の異性体が存在する場合は、いずれの異性体も、本発明の促進剤における前記有効成分として用いることができる。例えば、前記化学式(1)は、炭素−炭素二重結合に対し、E型の幾何異性体を表しているが、その異性体であるZ型の幾何異性体も、前記有効成分に含まれる。また、前記化学式(1)で表される化合物、その互変異性体、幾何異性体または立体異性体の塩も、同様に本発明に用いることができる。前記塩は、医学的または薬学的に許容可能な塩であることが好ましい。前記塩は、酸付加塩でも塩基付加塩でもよい。さらに、前記酸付加塩を形成する酸は無機酸でも有機酸でも良く、前記塩基付加塩を形成する塩基は無機塩基でも有機塩基でもよい。前記無機酸としては、特に限定されないが、例えば、硫酸、リン酸、フッ化水素酸、塩酸、臭化水素酸、ヨウ化水素酸、次亜フッ素酸、次亜塩素酸、次亜臭素酸、次亜ヨウ素酸、亜フッ素酸、亜塩素酸、亜臭素酸、亜ヨウ素酸、フッ素酸、塩素酸、臭素酸、ヨウ素酸、過フッ素酸、過塩素酸、過臭素酸、過ヨウ素酸等が挙げられる。前記有機酸も特に限定されないが、例えば、p−トルエンスルホン酸、メタンスルホン酸、シュウ酸、p−ブロモベンゼンスルホン酸、炭酸、コハク酸、クエン酸、安息香酸、酢酸、ヒドロキシカルボン酸、プロピオン酸、マロン酸、アジピン酸、フマル酸、マレイン酸等が挙げられる。前記無機塩基としては、特に限定されないが、例えば、水酸化アンモニウム、アルカリ金属水酸化物、アルカリ土類金属水酸化物、炭酸塩、炭酸水素塩、硫酸塩等があげられ、より具体的には、例えば、水酸化ナトリウム、水酸化カリウム、炭酸カリウム、炭酸ナトリウム、炭酸水素ナトリウム、炭酸水素カリウム、水酸化カルシウム、炭酸カルシウム、硫酸カリウム、硫酸カルシウム等が挙げられる。前記有機塩基も特に限定されないが、例えば、アルコールアミン、トリアルキルアミン、テトラアルキルアンモニウム、およびトリス(ヒドロキシメチル)アミノメタン等が挙げられる。前記アルコールアミンとしては、例えば、エタノールアミン等が挙げられる。前記トリアルキルアミンとしては、例えば、トリメチルアミン、トリエチルアミン、トリプロピルアミン、トリブチルアミン、トリオクチルアミン等が挙げられる。前記テトラアルキルアンモニウムとしては、例えば、テトラメチルアンモニウム、テトラエチルアンモニウム、テトラプロピルアンモニウム、テトラブチルアンモニウム、テトラオクチルアンモニウム等が挙げられる。これらの塩の製造方法も特に限定されず、例えば、前記レスベラトロール、レスベラトロール誘導体、それらの互変異性体、幾何異性体または立体異性体に、前記のような酸または塩基を公知の方法により適宜付加させる等の方法で製造することができる。 As described above, the compound represented by the chemical formula (1) includes isomers such as tautomers, geometric isomers, and stereoisomers (for example, conformers, optical isomers, etc.). In that case, any isomer can be used as the active ingredient in the promoter of the present invention. For example, the chemical formula (1) represents an E-type geometric isomer with respect to the carbon-carbon double bond, but the Z-type geometric isomer is also included in the active ingredient. Moreover, the compound represented by the chemical formula (1), its tautomer, geometric isomer or stereoisomer salt can also be used in the present invention. The salt is preferably a medically or pharmaceutically acceptable salt. The salt may be an acid addition salt or a base addition salt. Furthermore, the acid forming the acid addition salt may be an inorganic acid or an organic acid, and the base forming the base addition salt may be an inorganic base or an organic base. The inorganic acid is not particularly limited. For example, sulfuric acid, phosphoric acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, hypofluorite, hypochlorous acid, hypobromite, Hypoiodous acid, fluorinated acid, chlorous acid, bromic acid, iodic acid, fluoric acid, chloric acid, bromic acid, iodic acid, perfluoric acid, perchloric acid, perbromic acid, periodic acid, etc. Can be mentioned. Although the organic acid is not particularly limited, for example, p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromobenzenesulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, hydroxycarboxylic acid, propionic acid , Malonic acid, adipic acid, fumaric acid, maleic acid and the like. Examples of the inorganic base include, but are not limited to, ammonium hydroxide, alkali metal hydroxide, alkaline earth metal hydroxide, carbonate, bicarbonate, sulfate, and the like. More specifically, Examples thereof include sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, calcium hydroxide, calcium carbonate, potassium sulfate, calcium sulfate and the like. The organic base is not particularly limited, and examples thereof include alcohol amine, trialkylamine, tetraalkylammonium, and tris (hydroxymethyl) aminomethane. Examples of the alcohol amine include ethanolamine. Examples of the trialkylamine include trimethylamine, triethylamine, tripropylamine, tributylamine, and trioctylamine. Examples of the tetraalkylammonium include tetramethylammonium, tetraethylammonium, tetrapropylammonium, tetrabutylammonium, tetraoctylammonium and the like. The method for producing these salts is also not particularly limited. For example, the above-mentioned acids or bases are known as resveratrol, resveratrol derivatives, tautomers, geometric isomers or stereoisomers thereof. It can manufacture by the method of adding suitably according to the method.
また、本発明の促進剤は、前記レスベラトロール、レスベラトロール誘導体、それらの互変異性体、幾何異性体および立体異性体、ならびにそれらの塩からなる群から選択される少なくとも一つの有効成分以外の物質を含んでいてもよいし、含んでいなくてもよい。 The promoter of the present invention is at least one active ingredient selected from the group consisting of the resveratrol, resveratrol derivatives, tautomers, geometric isomers and stereoisomers thereof, and salts thereof. Substances other than those may or may not be included.
本発明において、前記核酸は、前述のように、RNA干渉によりmRNAの発現を抑制する核酸であり、例えば、miRNA、siRNA、shRNA等があげられ、これらの中でも、miRNAが特に好ましい。前記核酸は、例えば、疾患に関連する遺伝子のmRNA発現を抑制する核酸であることが好ましい。 In the present invention, as described above, the nucleic acid is a nucleic acid that suppresses the expression of mRNA by RNA interference. Examples thereof include miRNA, siRNA, shRNA, and among these, miRNA is particularly preferable. The nucleic acid is preferably a nucleic acid that suppresses mRNA expression of a gene related to a disease, for example.
本発明の促進剤は、前述のように、前記核酸の転写促進、およびArgonaute2(Ago2)の発現促進の少なくとも一方により、RNA干渉によるmRNAの発現抑制を促進する。このため、本発明の促進剤は、例えば、RNA干渉を利用した疾患の治療方法、医薬品、食品添加物、ノックダウンによる遺伝子解析等に適用できる。 As described above, the promoter of the present invention promotes the suppression of mRNA expression by RNA interference by at least one of the above-described nucleic acid transcription promotion and Argonaute2 (Ago2) expression promotion. Therefore, the promoter of the present invention can be applied to, for example, a disease treatment method using RNA interference, a pharmaceutical, a food additive, a gene analysis by knockdown, and the like.
(治療方法)
本発明の治療方法は、特定の遺伝子が関与する疾患を治療する方法であって、前記遺伝子は、RNA干渉によりmRNAの発現が抑制される遺伝子であり、前記本発明の促進剤により、RNA干渉によりmRNAの発現を抑制する核酸の転写、およびArgonaute2(Ago2)の発現の少なくとも一方を促進させることを特徴とする。本発明の治療方法は、前記本発明の促進剤の記載を引用できる。(Method of treatment)
The treatment method of the present invention is a method of treating a disease involving a specific gene, wherein the gene is a gene whose mRNA expression is suppressed by RNA interference, and the promoter of the present invention causes RNA interference. It promotes at least one of transcription of nucleic acid that suppresses mRNA expression and expression of Argonaute2 (Ago2). For the treatment method of the present invention, the description of the promoter of the present invention can be cited.
本発明の治療方法では、例えば、さらに、前記遺伝子のmRNAの発現をRNA干渉により抑制する外因性の核酸を投与してよい。このように、外因性の核酸を投与することにより、例えば、より効果的に疾患を治療できる。前記外因性の核酸は、例えば、前述の核酸を使用できる。 In the treatment method of the present invention, for example, an exogenous nucleic acid that suppresses the expression of mRNA of the gene by RNA interference may be administered. Thus, for example, a disease can be treated more effectively by administering an exogenous nucleic acid. As the exogenous nucleic acid, for example, the aforementioned nucleic acid can be used.
前記疾患は、特定の遺伝子が関与する疾患であり、例えば、がん、アルツハイマー、糖尿病等があげられる。前記外因性の核酸は、前記疾患に関与する遺伝子に応じて、適宜設定できる。 The disease is a disease in which a specific gene is involved, and examples thereof include cancer, Alzheimer, and diabetes. The exogenous nucleic acid can be appropriately set according to the gene involved in the disease.
(医薬品)
本発明の医薬品は、特定の遺伝子が関与する疾患を治療する医薬品であって、前記遺伝子は、RNA干渉により発現が抑制される遺伝子であり、前記本発明の促進剤と、前記遺伝子のmRNAの発現をRNA干渉により抑制する外因性の核酸とを含み、前記本発明の促進剤が、前記外因性の核酸の転写、およびArgonaute2(Ago2)の発現の少なくとも一方を促進することを特徴とする。本発明の医薬品は、前記本発明の促進剤および前記本発明の治療方法の記載を引用できる。(Medicine)
The pharmaceutical agent of the present invention is a pharmaceutical agent for treating a disease involving a specific gene, wherein the gene is a gene whose expression is suppressed by RNA interference, and the promoter of the present invention and the mRNA of the gene And an exogenous nucleic acid that suppresses expression by RNA interference, wherein the promoter of the present invention promotes at least one of transcription of the exogenous nucleic acid and expression of Argonaute2 (Ago2). For the pharmaceutical of the present invention, the description of the promoter of the present invention and the treatment method of the present invention can be cited.
本発明の医薬品の投与方法は、特に制限されず、例えば、経口投与でもよいし、非経口投与でもよい。経口剤として投与する時の形態は、特に限定されず、通常のおよび腸溶性錠剤、カプセル、ピル、散剤、顆粒剤、エリキシル剤、チンキ剤、溶剤、懸濁剤、シロップ、固体または液体エアロゾル、ならびに乳濁液等、当業者が通常用いる形態を選択することができる。また、前記非経口投与は、例えば、静脈注射、筋肉注射、皮下投与、直腸投与、経皮投与、腹腔内投与、局所投与等があげられる。本発明の医薬品の投与量は、特に制限されず、例えば、患者の体の大きさ、年齢、性別、病状の進行状況等により適宜決定される。 The administration method of the pharmaceutical agent of the present invention is not particularly limited, and may be, for example, oral administration or parenteral administration. The form when administered as an oral preparation is not particularly limited, and normal and enteric-coated tablets, capsules, pills, powders, granules, elixirs, tinctures, solvents, suspensions, syrups, solid or liquid aerosols, In addition, a form usually used by those skilled in the art, such as an emulsion, can be selected. Examples of the parenteral administration include intravenous injection, intramuscular injection, subcutaneous administration, rectal administration, transdermal administration, intraperitoneal administration, and local administration. The dosage of the pharmaceutical agent of the present invention is not particularly limited, and is appropriately determined depending on, for example, the size of the patient's body, age, sex, progress of the medical condition, and the like.
本発明の医薬品は、例えば、一種類以上の医学的または薬学的に許容可能な添加物をさらに含んでいてもよい。すなわち、例えば、前記本発明の促進剤を、投与に先立ち、一種類以上の薬学的または医学的に許容可能な添加物と共に製剤してもよい。前記添加物は、特に限定されないが、例えば、担体、希釈剤、香料、甘味料、滑沢剤、溶解剤、懸濁剤、結合剤、錠剤崩壊剤、およびカプセル化材等の不活性物質である。また、これら以外にも、例えば、医薬の分野で一般に使用されている任意の添加物を適宜用いても良い。 The medicament of the present invention may further contain, for example, one or more kinds of medically or pharmaceutically acceptable additives. That is, for example, the accelerator of the present invention may be formulated with one or more pharmaceutically or medically acceptable additives prior to administration. The additive is not particularly limited, and examples thereof include inert substances such as carriers, diluents, fragrances, sweeteners, lubricants, solubilizers, suspending agents, binders, tablet disintegrating agents, and encapsulating materials. is there. Besides these, for example, any additive generally used in the field of medicine may be used as appropriate.
(食品添加剤)
本発明の食品添加物は、特定の遺伝子が関与する疾患を予防または改善する食品添加剤であって、前記遺伝子は、RNA干渉により発現が抑制される遺伝子であり、前記本発明の促進剤を含むことを特徴とする。本発明の食品添加物は、前記本発明の促進剤を含むことが特徴であって、これ以外の構成は特に制限されない。本発明の食品添加物は、前記本発明の促進剤および前記本発明の医薬品の記載を引用できる。(Food additive)
The food additive of the present invention is a food additive for preventing or ameliorating a disease involving a specific gene, wherein the gene is a gene whose expression is suppressed by RNA interference, and the promoter of the present invention is It is characterized by including. The food additive of the present invention is characterized in that it contains the accelerator of the present invention, and other configurations are not particularly limited. For the food additive of the present invention, the description of the promoter of the present invention and the pharmaceutical product of the present invention can be cited.
(ノックダウン方法)
本発明のノックダウン方法は、RNA干渉により標的遺伝子をノックダウンする方法であって、前記標的遺伝子のmRNAの発現を抑制する外因性の核酸を細胞に導入する工程を含み、レスベラトロール(resveratrol)およびプテロスチルベン(pterostilbene)の少なくとも一つにより、前記導入された外因性の核酸の転写、およびArgonaute2(Ago2)の発現の少なくとも一方を促進させることを特徴とする。本発明のノックダウン方法によれば、前記レスベラトロールおよび前記プテロスチルベンの少なくとも一方により、前記細胞内において、前記外因性の核酸によるRNA干渉作用が促進され、前記標的遺伝子の発現が抑制される。このため、本発明のノックダウン方法により、例えば、遺伝子の解析を良好に行える。本発明のノックダウン方法は、前記本発明の促進剤の記載を引用できる。前記核酸の導入工程は、特に制限されず、例えば、従来公知の方法により行え、前記外因性の核酸は、前記標的遺伝子の種類に応じて適宜設定できる。また、前記細胞の種類または形態等は、特に制限されない。(Knockdown method)
The knockdown method of the present invention is a method of knocking down a target gene by RNA interference, which comprises a step of introducing an exogenous nucleic acid that suppresses the expression of mRNA of the target gene into a cell, and comprises resveratrol (resveratrol). ) And pterostilbene, at least one of the transcription of the introduced exogenous nucleic acid and the expression of Argonaute2 (Ago2) is promoted. According to the knockdown method of the present invention, at least one of the resveratrol and the pterostilbene promotes an RNA interference action by the exogenous nucleic acid in the cell and suppresses the expression of the target gene. . For this reason, for example, gene analysis can be favorably performed by the knockdown method of the present invention. For the knockdown method of the present invention, the description of the accelerator of the present invention can be cited. The step of introducing the nucleic acid is not particularly limited, and can be performed by, for example, a conventionally known method. The exogenous nucleic acid can be appropriately set according to the type of the target gene. Further, the type or form of the cells is not particularly limited.
つぎに、本発明の実施例について、説明する。本発明は、以下の実施例に限定されるものではない。 Next, examples of the present invention will be described. The present invention is not limited to the following examples.
(レスベラトロール、プテロスチルベン)
(1)レスベラトロール(cayman chemical社製)
(2)プテロスチルベン(東京化成工業社製)(Resveratrol, pterostilbene)
(1) Resveratrol (manufactured by cayman chemical)
(2) Pterostilbene (manufactured by Tokyo Chemical Industry Co., Ltd.)
(細胞)
細胞は、下記(1)〜(4)の細胞を使用した。
(1)MDA-MB231D3H2LN細胞(Xenogen社製)
(2)MCF7-ADR細胞(入手元:American Type Culture Collection)
(3)Ago2強制発現MDA-MB231D3H2LN細胞(Xenogen社製)
(4)Ago2強制発現HEK293細胞(Xenogen社製)(cell)
The following cells (1) to (4) were used.
(1) MDA-MB231D3H2LN cells (Xenogen)
(2) MCF7-ADR cells (Source: American Type Culture Collection)
(3) Ago2 forced expression MDA-MB231D3H2LN cells (Xenogen)
(4) Ago2 forced expression HEK293 cells (Xenogen)
(個体動物)
(1)マウス(日本チャールズリバー社製)(Individual animal)
(1) Mouse (made by Charles River Japan)
(浸潤率(% invasion))
浸潤率は、下記の試薬器具を使用し、製造元の説明書の記載に従って測定した。
マトリゲル インベージョン チャンバー 24ウェル 8μm(BD社製)(Invasion rate (% invasion))
The infiltration rate was measured using the following reagent device according to the manufacturer's instructions.
Matrigel Invasion Chamber 24 well 8μm (BD)
(細胞生存率(%))
細胞生存率は、下記の試薬を使用し、製造元の説明書の記載に従って測定した。
TetraColor One(生化学バイオビジネス社製)(Cell viability (%))
Cell viability was measured according to the manufacturer's instructions using the following reagents.
TetraColor One (manufactured by Biochemical Biobusiness)
図1(C)に示す発光量は、下記のようにして測定、解析した。すなわち、まず、マウスにD-ルシフェリン(150mg/kg, Promega) を腹腔投与し、10分後にIVIS イメージングシステム(Xenogen)を用いて、発光量(Photon/sec)を測定した。前記発光量の測定結果を、LIVINGIMAGE 2.50 software(Xenogen)を用いて解析した。 The light emission amount shown in FIG. 1C was measured and analyzed as follows. That is, first, D-luciferin (150 mg / kg, Promega) was intraperitoneally administered to mice, and 10 minutes later, the amount of luminescence (Photon / sec) was measured using an IVIS imaging system (Xenogen). The measurement result of the light emission amount was analyzed using LIVINGIMAGE 2.50 software (Xenogen).
(腫瘍残存率(% of tumor))
腫瘍残存率は、下記のようにして測定した。すなわち、まず、前記機器であるIVISイメージングシステム(Xenogen)を用いて、発光量を測定した。前記発光量の測定結果を、LIVINGIMAGE 2.50 software(Xenogen)を用いて解析した。この解析結果から、腫瘍残存率を測定した。(Tumor remaining rate (% of tumor))
Tumor residual rate was measured as follows. That is, first, the amount of luminescence was measured using the IVIS imaging system (Xenogen) which is the device. The measurement result of the light emission amount was analyzed using LIVINGIMAGE 2.50 software (Xenogen). From this analysis result, the tumor remaining rate was measured.
(フローサイトメトリー)
がん幹細胞の割合を測定するために、下記の試薬および機器を使用した。
・抗ヒトCD44-FIT抗体(Becton Dickinson社製, clone L178)
・抗ヒトCD24-APC抗体(Biolegend社製, clone ML5)
・デスクトップセルソーターJSAN(ノベルサイエンス社製)(Flow cytometry)
The following reagents and equipment were used to measure the proportion of cancer stem cells.
Anti-human CD44-FIT antibody (Becton Dickinson, clone L178)
Anti-human CD24-APC antibody (Biolegend, clone ML5)
・ Desktop cell sorter JSAN (manufactured by Novell Science)
(miRNAおよびAgo2のmRNA発現量の測定)
(1)トータルRNAの抽出
がん細胞(MDA-MB231D3H2LN細胞またはMCF7-ADR細胞)に、レスベラトロールまたはプテロスチルベンを所定濃度で添加した。前記添加から48時間後に、RNA精製前の細胞の溶解液を、Qiazol(キアゲン社製)で処理した。前記処理した溶液から、miRNeasy Mini Kit(50)(キアゲン社製)を用いて、total RNAを抽出した。(Measurement of miRNA and Ago2 mRNA expression levels)
(1) Extraction of total RNA Resveratrol or pterostilbene was added at a predetermined concentration to cancer cells (MDA-MB231D3H2LN cells or MCF7-ADR cells). 48 hours after the addition, the cell lysate before RNA purification was treated with Qiazol (Qiagen). Total RNA was extracted from the treated solution using miRNeasy Mini Kit (50) (Qiagen).
(2)リアルタイムPCT
(2−1)miRNAのリアルタイムPCR
miRNAに関しては、逆転写反応は、Taqmn miRNA assays Kitを用いて行った。すわなち、total RNA 1μgに、100mM dNTPs(with dTTP) 0.05μL、MultiScribe(登録商標)Reverse Transcriptase(50U/μL) 0.33μL、10×Reverse Transcription Buffer 0.50μL、RNase Inhibitor(20U/μL) 0.063μL、Nuclease-free water 1.387μL、そしてそれぞれのmiRNAに対応する5×RT primer(ID number; miR-16:000391、miR-141:000463、miR-143:002249、miR-200c:002300)を添加した。この混合物を、16℃・5分間、42℃・30分間、85℃・30分間反応させた。(2) Real-time PCT
(2-1) Real-time PCR of miRNA
For miRNA, reverse transcription reaction was performed using Taqmn miRNA assays Kit. That is, total RNA 1μg, 100mM dNTPs (with dTTP) 0.05μL, MultiScribe (registered trademark) Reverse Transcriptase (50U / μL) 0.33μL, 10x Reverse Transcription Buffer 0.50μL, RNase Inhibitor (20U / μL) 0.063μL , Nuclease-free water 1.387 μL, and 5 × RT primer (ID number; miR-16: 000391, miR-141: 000463, miR-143: 002249, miR-200c: 002300) corresponding to each miRNA were added . This mixture was reacted at 16 ° C. for 5 minutes, 42 ° C. for 30 minutes, and 85 ° C. for 30 minutes.
リアルタイムPCRは、TaqMan 2X Universal PCR Master Mix, No AmpErase UNG 5μL、20×TaqMan(登録商標)Small RNA Assay 0.5μL、鋳型として4倍希釈したRT反応物を4.5μL添加した、10μLの反応系で行った。リアルタイムPCRのプログラムは、95℃で10分間反応させたのち、95℃・15秒、60℃・60秒の反応を1サイクルとし、このサイクルを40回繰り返すプログラムとした。蛍光強度を、60℃の反応終了時に測定した。 Real-time PCR is performed in a 10 μL reaction system with TaqMan 2X Universal PCR Master Mix, No AmpErase UNG 5 μL, 20 × TaqMan® Small RNA Assay 0.5 μL, and 4.5 μL of RT reaction diluted 4-fold as a template. It was. The real-time PCR program was a program in which the reaction at 95 ° C. for 15 minutes and the reaction at 95 ° C. for 15 seconds and 60 ° C. for 60 seconds was performed as one cycle, and this cycle was repeated 40 times. The fluorescence intensity was measured at the end of the reaction at 60 ° C.
(2−2)Ago2のリアルタイムPCR
Ago2に関しては、逆転写反応は、High Capacity cDNA Reverse Transcription Kitを用いて行った。total RNA 1μgに、100mM dNTPs(with dTTP) 0.8μL、MultiScribe(登録商標)Reverse Transcriptase(50U/μL) 0.8μL、10×Reverse Transcription Buffer 2μL、RNase Inhibitor(20U/μL) 0.5μL、10×RT random Primer 2μLを添加し、そして、Nuclease-free waterを、混合物全体が20μLになるように添加した。この混合物を、25℃・10分間、37℃・120分間、85℃・1分間反応させた。(2-2) Real-time PCR of Ago2
For Ago2, the reverse transcription reaction was performed using the High Capacity cDNA Reverse Transcription Kit. Total RNA 1 μg, 100 mM dNTPs (with dTTP) 0.8 μL, MultiScribe (registered trademark) Reverse Transcriptase (50 U / μL) 0.8 μL, 10 × Reverse Transcription Buffer 2 μL, RNase Inhibitor (20 U / μL) 0.5 μL, 10 × RT random 2 μL of Primer was added and Nuclease-free water was added so that the total mixture was 20 μL. This mixture was reacted at 25 ° C. for 10 minutes, 37 ° C. for 120 minutes, and 85 ° C. for 1 minute.
リアルタイムPCRは、Platinum qPCR SuperMix-UDG with ROX 5μL、20×TaqMan(登録商標)probe(ID number; Ago2:Hs01085579_m1、TARBP2:Hs00366328_m1、DICER1:Hs00229023_m1、DROSHA6:Hs00203008_m1、DGCR8:Hs00377897_m1) 0.5μL、鋳型として10倍希釈したRT反応物を4.5μL添加した、10μLの反応系で行った。リアルタイムPCRのプログラムは、50℃・2分間および95℃・2分間反応させたのち、95℃・15秒、60℃・30秒の反応を1サイクルとし、このサイクルを45回繰り返すプログラムとした。蛍光強度を、60℃の反応終了時に測定した。 Real-time PCR is Platinum qPCR SuperMix-UDG with ROX 5 μL, 20 × TaqMan® probe (ID number; Ago2: Hs01085579_m1, TARBP2: Hs00366328_m1, DICER1: Hs00229023_m1, DROSHA6: Hs00203008_m1, 0.578 μm, DGCR97_H1, 0.58 The reaction was performed in a 10 μL reaction system to which 4.5 μL of a 10-fold diluted RT reaction was added. The real-time PCR program was a program in which the reaction at 95 ° C. for 15 seconds and at 60 ° C. for 30 seconds was performed as one cycle after reacting at 50 ° C. for 2 minutes and 95 ° C. for 2 minutes, and this cycle was repeated 45 times. The fluorescence intensity was measured at the end of the reaction at 60 ° C.
図1〜6におけるグラフについて、「*」は、P<0.05を示し、「**」は、P<0.01を示し、「***」は、P<0.001を示す。 1 to 6, “*” indicates P <0.05, “**” indicates P <0.01, and “***” indicates P <0.001.
[実施例1−1]
本実施例では、レスベラトロールの、がん細胞の浸潤への影響を確認した。[Example 1-1]
In this example, the effect of resveratrol on cancer cell invasion was confirmed.
がん細胞は、MDA-MB231D3H2LN細胞を使用した。前記がん細胞に、レスベラトロールを5μM(μmol/L)〜50μM(μmol/L)で添加した。前記がん細胞について、顕微鏡観察、浸潤率(% invasion)の測定を行った。コントロール(vehicle)は、レスベラトロールに代えて、DMSOを添加し、同様にして顕微鏡観察、浸潤率の測定を行った。 As cancer cells, MDA-MB231D3H2LN cells were used. Resveratrol was added to the cancer cells at 5 μM (μmol / L) to 50 μM (μmol / L). The cancer cells were observed with a microscope and measured for infiltration rate (% invasion). As a control (vehicle), DMSO was added instead of resveratrol, and microscopic observation and measurement of the infiltration rate were performed in the same manner.
図1(A)の写真およびグラフに示すように、レスベラトロールは、濃度依存的に、悪性度の高いMDA-MB231D3H2LN細胞の浸潤を抑制することが確認された。すなわち、図1(A)の顕微鏡写真に示すとおり、がん細胞を示す黒点は、レスベラトロール濃度依存的に減少し、この結果は、同図のグラフにおいて、浸潤率(% invasion)がレスベラトロール濃度依存的に減少したことと一致した。 As shown in the photograph and graph of FIG. 1 (A), it was confirmed that resveratrol suppresses the invasion of MDA-MB231D3H2LN cells having high malignancy in a concentration-dependent manner. That is, as shown in the micrograph of FIG. 1A, the black spots indicating cancer cells decrease depending on the resveratrol concentration, and this result shows that the invasion rate (% invasion) in the graph of FIG. This was consistent with the decrease in veratrol concentration.
[実施例1−2]
本実施例では、レスベラトロールの、がん細胞のドセタキセルに対する薬剤感受性への影響を確認した。[Example 1-2]
In this example, the effect of resveratrol on drug sensitivity of cancer cells to docetaxel was confirmed.
がん細胞は、MDA-MB231D3H2LN細胞を使用した。前記がん細胞に、レスベラトロールを25μM(μmol/L)およびドセタキセル(Docetaxel)を2.5nM(nmol/L)添加した。前記がん細胞について、細胞生存率(Cell viability(%))の測定を行った。コントロール(vehicle)は、レスベラトロールおよびドセタキセルに代えて、DMSOを添加し、同様にして細胞生存率の測定を行った。 As cancer cells, MDA-MB231D3H2LN cells were used. Resveratrol 25 μM (μmol / L) and docetaxel 2.5 nM (nmol / L) were added to the cancer cells. Cell viability (Cell viability (%)) was measured for the cancer cells. Control (vehicle) was replaced with resveratrol and docetaxel, DMSO was added, and the cell viability was measured similarly.
図1(B)のグラフに示すように、レスベラトロールは、MDA-MB231D3H2LN細胞の抗がん剤であるドセタキセルに対する薬剤感受性を向上させることが確認された。 As shown in the graph of FIG. 1 (B), it was confirmed that resveratrol improves the drug sensitivity of MDA-MB231D3H2LN cells to docetaxel, which is an anticancer agent.
[実施例1−3]
本実施例では、レスベラトロールの、in vivoでの腫瘍形成および薬剤感受性への影響を確認した。[Example 1-3]
In this example, the effect of resveratrol on tumor formation and drug sensitivity in vivo was confirmed.
個体動物は、SCID Hairless Outbred(SHO)マウスを使用した。前記動物の腹部に、がん細胞であるMDA-MB231D3H2LN細胞を移植した。この状態で、前記動物に、レスベラトロールを、16.5mg/kg/dayで投与した。また、別個体の前記動物に、レスベラトロールおよびドセタキセルを、16.5mg/kg/dayおよび10mg/kg/weekで投与した。前記投与後の動物における腹部のがん細胞について、発光量(Photon/sec)の測定および解析、ならびに腫瘍残存率(% of tumor)の測定を行った。レスベラトロールを投与した実験のコントロール(vehicle)は、レスベラトロールに代えて、エタノールを投与し、同様にして発光量の測定および解析を行った。レスベラトロールおよびドセタキセルを投与した実験のコントロール(vehicle)は、ドセタキセルを投与し、同様にして腫瘍残存率を測定した。 As an individual animal, a SCID Hairless Outbred (SHO) mouse was used. MDA-MB231D3H2LN cells, which are cancer cells, were transplanted into the abdomen of the animals. In this state, resveratrol was administered to the animals at 16.5 mg / kg / day. In addition, resveratrol and docetaxel were administered to separate animals at 16.5 mg / kg / day and 10 mg / kg / week. The abdominal cancer cells in the animals after the administration were measured and analyzed for the amount of luminescence (Photon / sec) and the tumor residual rate (% of tumor). The control (vehicle) in which resveratrol was administered was administered with ethanol instead of resveratrol, and the amount of luminescence was measured and analyzed in the same manner. The control (vehicle) of the experiment in which resveratrol and docetaxel were administered administered docetaxel, and the tumor residual rate was measured in the same manner.
図1(C)の写真およびグラフ、ならびに図1(D)のグラフに示すように、レスベラトロールは、in vivoで、MDA-MB231D3H2LN細胞の腫瘍形成を抑制し、抗がん剤であるドセタキセルに対する薬剤感受性を向上させることが確認された。図1(C)左側の写真に示すように、コントロール(vehicle)マウスでは、同図中「a」および「b」で示す円で囲った位置に、腹腔内の腫瘍に由来する発光が確認された。これに対し、図1(C)右側の写真に示すレスベラトロール投与マウスは、発光量が小さいために(図1(C)のグラフ参照)、この写真では発光が確認できなかった。また、図1(D)のグラフに示すように、レスベラトロール投与マウスは、投与後22日(Day 22)および29日(Day 29)のいずれでも、コントロール(vehicle)マウスより腫瘍残存率(% of tumor)が小さく、特に、投与後29日では、腫瘍残存率がきわめて低くなっていた。As shown in the photograph and graph of FIG. 1 (C) and the graph of FIG. 1 (D), resveratrol suppresses tumor formation of MDA-MB231D3H2LN cells in vivo and is an anticancer agent, docetaxel It was confirmed that the drug sensitivity to the drug was improved. As shown in the photograph on the left side of FIG. 1 (C), in the control (vehicle) mouse, luminescence derived from the tumor in the abdominal cavity was confirmed at the position surrounded by the circles indicated by “a” and “b” in the same figure. It was. In contrast, the resveratrol-administered mouse shown in the photograph on the right side of FIG. 1 (C) has a small amount of luminescence (see the graph in FIG. 1 (C)), and thus luminescence could not be confirmed in this photograph. Moreover, as shown in the graph of FIG. 1 (D), resveratrol-administered mice were more likely to have tumor residual rate than control mice (Day 22) and 29 (Day 29) after administration. % of tumor) was small, and especially on the 29th day after administration, the tumor residual rate was extremely low.
[実施例2−1]
本実施例では、レスベラトロールの、がん細胞のがん幹細胞の割合(CD24-/CD44+)への影響を確認した。[Example 2-1]
In this example, the effect of resveratrol on the ratio of cancer stem cells to cancer cells (CD24− / CD44 +) was confirmed.
がん細胞は、MDA-MB231D3H2LN細胞を使用した。前記がん細胞に、レスベラトロールを5μM(μmol/L)〜50μM(μmol/L)で添加した。前記がん細胞について、フローサイトメトリー測定を行った。コントロール(0μM(μmol/L))は、レスベラトロールに代えて、DMSOを添加し、同様にしてフローサイトメトリー測定を行った。 As cancer cells, MDA-MB231D3H2LN cells were used. Resveratrol was added to the cancer cells at 5 μM (μmol / L) to 50 μM (μmol / L). Flow cytometry measurement was performed on the cancer cells. As a control (0 μM (μmol / L)), DMSO was added instead of resveratrol, and flow cytometry measurement was performed in the same manner.
図2(A)のフローサイトメトリーおよびグラフに示すように、レスベラトロールは、濃度依存的に、MDA-MB231D3H2LN細胞のがん幹細胞(CD24-/CD44+)の割合(Percentage of CD24-/CD44+)を減少させることが確認された。 As shown in the flow cytometry and graph of FIG. 2 (A), resveratrol is a concentration-dependent ratio of cancer stem cells (CD24- / CD44 +) to MDA-MB231D3H2LN cells (Percentage of CD24- / CD44 +). Was confirmed to decrease.
[実施例2−2]
本実施例では、レスベラトロールの、がん細胞におけるがん幹細胞を抑制するmiRNAであるmiR-200cの発現への影響を確認した。[Example 2-2]
In this example, the effect of resveratrol on the expression of miR-200c, a miRNA that suppresses cancer stem cells in cancer cells, was confirmed.
がん細胞は、MDA-MB231D3H2LN細胞を使用した。前記がん細胞に、レスベラトロールを25μM(μmol/L)または50μM(μmol/L)で添加した。前記がん細胞について、相対的miRNA発現量を測定した。コントロール(0μM(μmol/L))は、レスベラトロールに代えて、DMSOを添加し、同様にして相対的miRNA発現量(Comparative expression of miR-200c)を測定した。 As cancer cells, MDA-MB231D3H2LN cells were used. Resveratrol was added to the cancer cells at 25 μM (μmol / L) or 50 μM (μmol / L). The relative miRNA expression level was measured for the cancer cells. As a control (0 μM (μmol / L)), DMSO was added instead of resveratrol, and the relative miRNA expression level (Comparative expression of miR-200c) was measured in the same manner.
図2(B)のグラフに示すように、レスベラトロールは、MDA-MB231D3H2LN細胞におけるがん幹細胞を抑制するmiRNAであるmiR-200cの発現を上昇させることが確認された。 As shown in the graph of FIG. 2 (B), it was confirmed that resveratrol increases the expression of miR-200c, which is a miRNA that suppresses cancer stem cells in MDA-MB231D3H2LN cells.
上記実施例2−1および実施例2−2の結果から、レスベラトロールがmiRNAの発現(転写)を促進することが確認され、この結果、がん幹細胞が抑制されることが確認された。 From the results of Example 2-1 and Example 2-2, it was confirmed that resveratrol promotes miRNA expression (transcription), and as a result, it was confirmed that cancer stem cells were suppressed.
[実施例3−1]
本実施例では、レスベラトロールの、がん細胞におけるがん抑制的なmiRNAであるmiR-16、miR-141、miR-143の発現への影響を確認した。[Example 3-1]
In this example, the effect of resveratrol on the expression of miR-16, miR-141, and miR-143, which are tumor suppressor miRNAs in cancer cells, was confirmed.
がん細胞は、MDA-MB231D3H2LN細胞を使用した。前記がん細胞に、レスベラトロールを25μM(μmol/L)または50μM(μmol/L)で添加した。前記がん細胞について、相対的miRNA発現量(Comparative expression of miR-16、miR-141、miR-143)を測定した。コントロール(0μM(μmol/L))は、レスベラトロールに代えてDMSOを添加し、同様にして相対的miRNA発現量を測定した。 As cancer cells, MDA-MB231D3H2LN cells were used. Resveratrol was added to the cancer cells at 25 μM (μmol / L) or 50 μM (μmol / L). About the said cancer cell, the relative miRNA expression level (Comparative expression of miR-16, miR-141, miR-143) was measured. As a control (0 μM (μmol / L)), DMSO was added instead of resveratrol, and the relative miRNA expression level was measured in the same manner.
図3(A)のグラフに示すように、レスベラトロールは、MDA-MB231D3H2LN細胞におけるがん抑制的なmiRNAであるmiR-16、miR-141、miR-143の発現を上昇させることが確認された。 As shown in the graph of FIG. 3 (A), resveratrol was confirmed to increase the expression of miR-16, miR-141, and miR-143, which are tumor suppressor miRNAs, in MDA-MB231D3H2LN cells. It was.
[実施例3−2]
本実施例では、がんの浸潤を抑制するmiR-141の発現減少による、レスベラトロールの浸潤抑制効果への影響を確認した。[Example 3-2]
In the present Example, the influence on the invasion suppression effect of resveratrol by the expression reduction of miR-141 which suppresses cancer invasion was confirmed.
がん細胞は、MDA-MB231D3H2LN細胞を使用した。前記がん細胞に、Anti-miR-141(Ambion社製)を、トランスフェクション試薬であるDharmaFECT 1(0.2μL)を用いて、100nM(nmol/L)で添加した。ついで、Anti-miR-141を添加したがん細胞(Anti-miR-141)および添加していないがん細胞(Anti-miR-NC)に、レスベラトロールを50μM(μmol/L)で添加した。前記がん細胞について、顕微鏡観察および浸潤率(% invasion)の測定を行った。コントロール(0μM(μmol/L))は、レスベラトロールに代えて、DMSOを添加し、同様にして浸潤率を測定した。 As cancer cells, MDA-MB231D3H2LN cells were used. Anti-miR-141 (manufactured by Ambion) was added to the cancer cells at 100 nM (nmol / L) using DharmaFECT 1 (0.2 μL) as a transfection reagent. Subsequently, resveratrol was added at 50 μM (μmol / L) to cancer cells to which Anti-miR-141 was added (Anti-miR-141) and to cancer cells to which Anti-miR-141 was not added (Anti-miR-NC). . The cancer cells were observed with a microscope and measured for invasion rate (% invasion). As a control (0 μM (μmol / L)), DMSO was added instead of resveratrol, and the infiltration rate was measured in the same manner.
図3(B)の写真およびグラフに示すように、浸潤を抑制するmiR-141の発現を減少させると、MDA-MB231D3H2LN細胞に対するレスベラトロールの浸潤抑制効果が低下することが確認された。すなわち、図3(B)の写真に示すように、Anti-miR-141を添加した場合(Anti-miR-141)の方が、添加しなかった場合(Anti-miR-NC)よりも、がん細胞を示す黒点が多く、この結果は、同図のグラフにおいて、Anti-miR-141の方がAnti-miR-NCよりも浸潤率(% invasion)が高かったことと一致した。 As shown in the photograph and graph of FIG. 3 (B), it was confirmed that the invasion inhibitory effect of resveratrol on MDA-MB231D3H2LN cells decreases when the expression of miR-141 that suppresses invasion is decreased. That is, as shown in the photograph of FIG. 3 (B), the case where Anti-miR-141 was added (Anti-miR-141) was more intensive than the case where Anti-miR-141 was not added (Anti-miR-NC). There are many black dots indicating cancer cells, and this result was consistent with the anti-miR-141 having higher invasion rate (% invasion) than Anti-miR-NC in the graph of FIG.
[実施例3−3]
本実施例では、がんの細胞増殖を抑制するmiR-143の発現減少による、レスベラトロールの細胞増殖抑制効果への影響を確認した。[Example 3-3]
In this example, the effect of resveratrol on the cell growth inhibitory effect due to the decreased expression of miR-143 that suppresses cancer cell growth was confirmed.
がん細胞は、MDA-MB231D3H2LN細胞を使用した。前記がん細胞に、Anti-miR-143(Ambion社製)を、トランスフェクション試薬であるDharmaFECT 1(0.2μL)を用いて、100nM(nmol/L)で添加した。ついで、前記がん細胞に、レスベラトロールを50μM(μmol/L)で添加した。前記がん細胞について、細胞生存率(cell viability (%))測定を行った。コントロール(0μM(μmol/L))は、レスベラトロールに代えて、DMSOを添加し、同様にして細胞生存率を測定した。 As cancer cells, MDA-MB231D3H2LN cells were used. Anti-miR-143 (Ambion) was added to the cancer cells at 100 nM (nmol / L) using DharmaFECT 1 (0.2 μL) as a transfection reagent. Next, resveratrol was added to the cancer cells at 50 μM (μmol / L). The cell viability (cell viability (%)) was measured for the cancer cells. As a control (0 μM (μmol / L)), DMSO was added instead of resveratrol, and the cell viability was measured in the same manner.
図3(C)のグラフに示すように、細胞増殖を抑制するmiR-143の発現を減少させると、MDA-MB231D3H2LN細胞に対するレスベラトロールの細胞増殖抑制効果が低下することが確認された。すなわち、同図に示すように、Anti-miR-141を添加した場合(Anti-miR-141)の方が、添加しなかった場合(Anti-miR-NC)よりも、細胞生存率(cell viability (%))が高かった。 As shown in the graph of FIG. 3 (C), it was confirmed that when the expression of miR-143 that suppresses cell growth is decreased, the cell growth inhibitory effect of resveratrol on MDA-MB231D3H2LN cells decreases. That is, as shown in the figure, the cell viability (anti-miR-141) when Anti-miR-141 was added (Anti-miR-141) was higher than that without (Anti-miR-NC). (%)) Was high.
上記実施例3−1〜3−3の結果から、レスベラトロールがmiRNAの発現(転写)を促進することにより、がん細胞の増殖を抑制することが確認された。 From the results of Examples 3-1 to 3-3, it was confirmed that resveratrol suppresses the growth of cancer cells by promoting the expression (transcription) of miRNA.
[実施例4−1]
本実施例では、レスベラトロールの、がん細胞におけるがん抑制的なmiRNAの発現への影響を、マイクロアレイを使用して確認した。[Example 4-1]
In this example, the effect of resveratrol on tumor suppressive miRNA expression in cancer cells was confirmed using a microarray.
がん細胞は、MDA-MB231D3H2LN細胞を使用した。前記がん細胞に、レスベラトロールを25μM(μmol/L)で添加した。コントロール(0μM(μmol/L))は、レスベラトロールに代えて、DMSOを添加した。前記添加から48時間後に、RNA精製前の細胞の溶解液を、Qiazol(キアゲン社製)で処理した。前記処理した溶液から、miRNeasy Mini Kit(50)(キアゲン社製)を用いて、total RNAを抽出した。前記total RNAを、マイクロアレイ(Agilent社製)に供して、miRNAの発現を測定した。 As cancer cells, MDA-MB231D3H2LN cells were used. Resveratrol was added to the cancer cells at 25 μM (μmol / L). As a control (0 μM (μmol / L)), DMSO was added instead of resveratrol. 48 hours after the addition, the cell lysate before RNA purification was treated with Qiazol (Qiagen). Total RNA was extracted from the treated solution using miRNeasy Mini Kit (50) (Qiagen). The total RNA was subjected to microarray (manufactured by Agilent), and miRNA expression was measured.
図4(A)のグラフに、前記マイクロアレイによるmiRNA発現の測定結果を示す。図4(A)において、縦軸は、レスベラトロールを25μM(μmol/L)で添加した群の個々のmiRNAの発現量を、横軸はレスベラトロール(0μM(μmol/L))を添加しなかった群の個々のmiRNAの発現量を示している。あるmiRNAの発現量がレスベラトロールを25μM(μmol/L)で添加した群とレスベラトロールを添加しなかった群とで等しい場合、直線(y=x)上にプロットが存在する。また、あるmiRNAの発現量がレスベラトロールを25μM(μmol/L)で添加した群がレスベラトロールを添加しなかった群より高い場合、直線(y=x)より上にプロットが存在する。図4(A)に示すように、レスベラトロールは、多数のがん抑制的なmiRNAの発現を上昇させることが確認された。 The graph of FIG. 4A shows the measurement results of miRNA expression by the microarray. In FIG. 4 (A), the vertical axis represents the expression level of each miRNA of the group to which resveratrol was added at 25 μM (μmol / L), and the horizontal axis represents resveratrol (0 μM (μmol / L)). The expression level of each individual miRNA in the group that did not. When the expression level of a certain miRNA is equal between the group to which resveratrol is added at 25 μM (μmol / L) and the group to which resveratrol is not added, a plot exists on a straight line (y = x). Further, when the expression level of a certain miRNA is higher in the group to which resveratrol is added at 25 μM (μmol / L) than the group to which resveratrol is not added, a plot exists above the straight line (y = x). As shown in FIG. 4 (A), it was confirmed that resveratrol increases the expression of many tumor-suppressing miRNAs.
[実施例4−2]
本実施例では、レスベラトロールの、がん細胞におけるAgo2の発現への影響を確認した。[Example 4-2]
In this example, the effect of resveratrol on the expression of Ago2 in cancer cells was confirmed.
がん細胞は、MCF7-ADR細胞を使用した。前記がん細胞に、レスベラトロールを50μM(μmol/L)で添加した。前記がん細胞について、Ago2の相対的mRNA発現量を測定した。 As cancer cells, MCF7-ADR cells were used. Resveratrol was added to the cancer cells at 50 μM (μmol / L). For the cancer cells, the relative mRNA expression level of Ago2 was measured.
図4(B)のグラフに、Ago2の相対的mRNA発現量の測定結果を示す。図4(B)において、縦軸は、相対的mRNA発現量(Comparative expression of mRNA(normalized with DMSO))を示し、横軸の1〜5は、それぞれ、1:Ago2、2:TARBP2、3:DICER1、4:DROSHA6、5:DGCR8を示す。Ago2、TARBP2、DICER1、DROSHA6、DGCR8は、全てmiRNAの生合成に関与する遺伝子である。図4(B)に示すように、レスベラトロールは、MCF7-ADR細胞において、Ago2の発現を上昇させることが確認された。 The measurement result of the relative mRNA expression level of Ago2 is shown in the graph of FIG. 4 (B). In FIG. 4B, the vertical axis indicates relative mRNA expression level (Comparative expression of mRNA (normalized with DMSO)), and 1 to 5 on the horizontal axis indicate 1: Ago2, 2: TARBP2, 3: DICER1, 4: DROSHA6, 5: DGCR8. Ago2, TARBP2, DICER1, DROSHA6, and DGCR8 are all genes involved in miRNA biosynthesis. As shown in FIG. 4 (B), it was confirmed that resveratrol increases the expression of Ago2 in MCF7-ADR cells.
上記実施例4−1および4−2の結果から、レスベラトロールは、miRNAの発現(転写)、およびAgo2の発現の両方を促進することが確認された。 From the results of Examples 4-1 and 4-2, it was confirmed that resveratrol promotes both miRNA expression (transcription) and Ago2 expression.
[実施例4−3]
本実施例では、Ago2を強制発現させたがん細胞における、miR-16およびmiR-143の発現を確認した。[Example 4-3]
In this example, the expression of miR-16 and miR-143 was confirmed in cancer cells in which Ago2 was forcibly expressed.
がん細胞は、Ago2を強制発現させたMDA-MB231D3H2LN細胞(Ago2 O/E)を使用した。前記がん細胞について、相対的miRNA発現量を測定した。コントロール(NC)は、Ago2を強制発現させていないMDA-MB231D3H2LN細胞について、同様にして相対的miRNA発現量(Comparative expression of miR-16、miR-143)を測定した。 As cancer cells, MDA-MB231D3H2LN cells (Ago2 O / E) in which Ago2 was forcibly expressed were used. The relative miRNA expression level was measured for the cancer cells. Control (NC) measured the relative miRNA expression level (Comparative expression of miR-16, miR-143) in the same manner for MDA-MB231D3H2LN cells in which Ago2 was not forcibly expressed.
図4(C)のグラフに示すように、MDA-MB231D3H2LN細胞においてAgo2を強制発現させた結果、miR-16、miR-143発現の上昇が確認された。 As shown in the graph of FIG. 4C, as a result of forced expression of Ago2 in MDA-MB231D3H2LN cells, an increase in miR-16 and miR-143 expression was confirmed.
[実施例4−4]
本実施例では、Ago2を強制発現させた細胞における、RNA干渉効果の持続性を確認した。[Example 4-4]
In this example, the persistence of the RNA interference effect in cells in which Ago2 was forcibly expressed was confirmed.
正常細胞として、Ago2強制発現HEK293細胞(HEK293 Ago2 O/E)を使用した。前記正常細胞について、相対的miRNA発現量を測定した。コントロール(HEK293)は、Ago2を強制発現させていないHEK293細胞について、同様にして相対的miRNA発現量を測定した。前記相対的miRNA発現量の測定は、図4(D)のグラフに示すように、前記各細胞におけるレニラルシファラーゼに対して規格化されたホタルルシファラーゼ活性に基づいて行った。前記各細胞におけるRNA干渉の効果を確認した。 Ago2 forced expression HEK293 cells (HEK293 Ago2 O / E) were used as normal cells. The relative miRNA expression level was measured for the normal cells. Control (HEK293) measured the relative miRNA expression level similarly about HEK293 cell which is not forcedly expressing Ago2. The relative miRNA expression level was measured based on firefly luciferase activity normalized to Renilla luciferase in each cell, as shown in the graph of FIG. 4 (D). The effect of RNA interference in each cell was confirmed.
図4(D)のグラフに示すように、HEK293細胞においてAgo2を強制発現させた結果、RNA干渉の効果がより持続されることが確認された。すなわち、同図に示すように、Ago2強制発現後5日(day 5)において、Ago2強制発現HEK293細胞(HEK293 Ago2 O/E)の方が、Ago2を強制発現させていないHEK293細胞(HEK293)よりも、ルシフェラーゼ活性(luciferase activity)が低かったことから、RNA干渉の効果がより持続されることが確認された。 As shown in the graph of FIG. 4D, it was confirmed that the effect of RNA interference was more sustained as a result of forced expression of Ago2 in HEK293 cells. That is, as shown in the figure, on day 5 after Ago2 forced expression, Ago2 forced expression HEK293 cells (HEK293 Ago2 O / E) are better than HEK293 cells (HEK293) not forcedly expressing Ago2. In addition, since the luciferase activity was low, it was confirmed that the RNA interference effect was more sustained.
上記実施例4−1〜4−4の結果から、細胞種に関わりなく、Ago2の発現が促進されることで、miRNAの発現(転写)が促進され、RNA干渉の効果が持続されることが確認された。すなわち、レスベラトロールにより、Ago2の発現およびmiRNAの転写が促進され、miRNAによるRNA干渉の効果が向上することが明らかである。 From the results of Examples 4-1 to 4-4, the expression (transcription) of miRNA is promoted and the effect of RNA interference is sustained by promoting the expression of Ago2, regardless of the cell type. confirmed. That is, it is clear that resveratrol promotes Ago2 expression and miRNA transcription, and improves the RNA interference effect by miRNA.
[実施例5−1]
本実施例では、レスベラトロールおよびプテロスチルベンの、がん細胞の細胞増殖への影響を確認した。[Example 5-1]
In this example, the effects of resveratrol and pterostilbene on cell proliferation of cancer cells were confirmed.
がん細胞は、MCF7細胞を使用した。前記がん細胞に、レスベラトロールを25μM(μmol/L)〜100μM(μmol/L)、または、プテロスチルベンを25μM(μmol/L)〜100μM(μmol/L)で添加した。前記がん細胞について、細胞生存率(cell viability (%))測定を行った。コントロール(0μM(μmol/L))は、レスベラトロールおよびプテロスチルベンに代えて、DMSOを添加し、同様にして細胞生存率測定を行った。 As cancer cells, MCF7 cells were used. Resveratrol was added to the cancer cells at 25 μM (μmol / L) to 100 μM (μmol / L) or pterostilbene at 25 μM (μmol / L) to 100 μM (μmol / L). The cell viability (cell viability (%)) was measured for the cancer cells. As a control (0 μM (μmol / L)), DMSO was added instead of resveratrol and pterostilbene, and the cell viability was measured in the same manner.
図5(A)のグラフに示すように、レスベラトロールおよびプテロスチルベンは、MCF7細胞の細胞増殖抑制効果を有することが確認された。プテロスチルベンは、レスベラトロールよりさらに優れた、MCF7細胞の細胞増殖抑制効果を有することが確認された。 As shown in the graph of FIG. 5 (A), it was confirmed that resveratrol and pterostilbene have a cell growth inhibitory effect on MCF7 cells. Pterostilbene was confirmed to have a cell growth inhibitory effect on MCF7 cells, which is superior to resveratrol.
[実施例5−2]
本実施例では、レスベラトロールおよびプテロスチルベンの、がん細胞におけるAgo2の発現への影響を確認した。[Example 5-2]
In this example, the effects of resveratrol and pterostilbene on the expression of Ago2 in cancer cells were confirmed.
がん細胞は、MDA-MB231D3H2LN細胞を使用した。前記がん細胞に、レスベラトロールを50μM(μmol/L)、またはプテロスチルベンを50μM(μmol/L)で添加した。前記がん細胞について、Ago2の相対的mRNA発現量(Relative expression of Ago2)を測定した。コントロール(vehicle)は、レスベラトロールおよびプテロスチルベンに代えて、DMSOを添加し、同様にしてAgo2の相対的mRNA発現量を測定した。 As cancer cells, MDA-MB231D3H2LN cells were used. Resveratrol was added to the cancer cells at 50 μM (μmol / L) or pterostilbene at 50 μM (μmol / L). About the said cancer cell, the relative mRNA expression level (Relative expression of Ago2) of Ago2 was measured. As a control (vehicle), DMSO was added instead of resveratrol and pterostilbene, and the relative mRNA expression level of Ago2 was measured in the same manner.
図5(B)のグラフに示すように、レスベラトロールおよびプテロスチルベンは、MDA-MB231D3H2LN細胞におけるAgo2の発現を上昇させることが確認され、プテロスチルベンは、レスベラトロールよりさらに優れて、MDA-MB231D3H2LN細胞におけるAgo2の発現を上昇させることが確認された。 As shown in the graph of FIG. 5 (B), resveratrol and pterostilbene were confirmed to increase the expression of Ago2 in MDA-MB231D3H2LN cells, and pterostilbene was superior to resveratrol, and MDA- It was confirmed that the expression of Ago2 in MB231D3H2LN cells was increased.
[実施例5−3]
本実施例では、レスベラトロールおよびプテロスチルベンの、がん細胞におけるmiRNAであるmiR-141、miR-143、miR-200cの発現への影響を確認した。[Example 5-3]
In this example, the effect of resveratrol and pterostilbene on the expression of miR-141, miR-143, and miR-200c, which are miRNAs in cancer cells, was confirmed.
がん細胞は、MDA-MB231D3H2LN細胞を使用した。前記がん細胞に、レスベラトロールを25μM(μmol/L)、またはプテロスチルベンを25μM(μmol/L)で添加した。前記添加から48時間後に、RNA生成前の細胞の溶解液を、Qiazol(キアゲン社製)で処理し、total RNAを抽出した。前記total RNA 1μgに、100mM dNTPs(with dTTP) 0.05μL、MultiScribe(登録商標)Reverse Transcriptase(50U/μL) 0.33μL、10×Reverse Transcription Buffer 0.50μL、RNase Inhibitor(20U/μL) 0.063μL、Nuclease-free water 1.387μL、そしてそれぞれのmiRNAに対応する5×RT primer(ID number; miR-16:000391、miR-141:000463、miR-143:002249、miR-200c:002300)を添加することにより、逆転写反応を行った。その後、リアルタイムPCRでmiR-141、miR-143、miR-200cを定量解析することにより、前記がん細胞について、miR-141、miR-143、miR-200cの相対的miRNA発現量(Relative expression of mRNA)を測定した。コントロール(vehicle)は、レスベラトロールおよびプテロスチルベンに代えて、DMSOを添加し、同様にして相対的miRNA発現量を測定した。 As cancer cells, MDA-MB231D3H2LN cells were used. Resveratrol was added to the cancer cells at 25 μM (μmol / L) or pterostilbene at 25 μM (μmol / L). 48 hours after the addition, the cell lysate before RNA production was treated with Qiazol (Qiagen) to extract total RNA. To 1 μg of the total RNA, 100 mM dNTPs (with dTTP) 0.05 μL, MultiScribe (registered trademark) Reverse Transcriptase (50 U / μL) 0.33 μL, 10 × Reverse Transcription Buffer 0.50 μL, RNase Inhibitor (20 U / μL) 0.063 μL, Nuclease- By adding 1.387 μL of free water and 5 × RT primer (ID number; miR-16: 000391, miR-141: 000463, miR-143: 002249, miR-200c: 002300) corresponding to each miRNA, Reverse transcription reaction was performed. Thereafter, miR-141, miR-143, and miR-200c are quantitatively analyzed by real-time PCR, whereby the miR-141, miR-143, and miR-200c relative miRNA expression levels (Relative expression of mRNA) was measured. Control (vehicle) was replaced with resveratrol and pterostilbene, added DMSO, and measured the relative miRNA expression level similarly.
図6のグラフに示すように、レスベラトロールおよびプテロスチルベンは、MDA-MB231D3H2LN細胞におけるmiR-141、miR-143、miR-200cの発現を上昇させることが確認され、プテロスチルベンは、レスベラトロールよりさらに優れて、MDA-MB231D3H2LN細胞におけるmiR-141、miR-143、miR-200cの発現を上昇させることが確認された。 As shown in the graph of FIG. 6, resveratrol and pterostilbene were confirmed to increase the expression of miR-141, miR-143, and miR-200c in MDA-MB231D3H2LN cells, and pterostilbene was resveratrol. It was confirmed that the expression of miR-141, miR-143, and miR-200c in MDA-MB231D3H2LN cells was further enhanced.
上記実施例5−1〜5−3の結果から、レスベラトロールに加えて、プテロスチルベンも、Ago2の発現とmiRNAの発現(転写)を促進することが確認され、その結果、がん細胞の増殖を抑制することが確認された。 From the results of Examples 5-1 to 5-3, in addition to resveratrol, it was confirmed that pterostilbene also promotes Ago2 expression and miRNA expression (transcription). It was confirmed that the growth was suppressed.
以上の実施例の結果から、レスベラトロールおよびプテロスチルベンは、miRNAの発現(転写)およびAgo2の発現を促進することが確認され、前記促進により、miRNAによるRNA干渉効果が促進されることが確認された。このため、本発明の促進剤は、例えば、特定の遺伝子が関連する疾患に対して、前記遺伝子に対するmiRNAのRNA干渉作用を促進することで、前記疾患の治療等に有用といえる。 From the results of the above examples, it is confirmed that resveratrol and pterostilbene promote the expression (transcription) of miRNA and the expression of Ago2, and it is confirmed that the RNA interference effect by miRNA is promoted by the promotion. It was done. For this reason, it can be said that the promoter of the present invention is useful for the treatment of the above-mentioned diseases, for example, by promoting the RNA interference action of miRNA against the above-mentioned genes for diseases related to a specific gene.
Claims (15)
前記有効成分が、RNA干渉によりmRNAの発現を抑制する核酸の転写、およびArgonaute2(Ago2)の発現の少なくとも一方を促進することを特徴とする促進剤。Comprising at least one active ingredient selected from the group consisting of resveratrol, resveratrol derivatives, tautomers, geometric isomers and stereoisomers thereof, and salts thereof;
A promoter characterized in that the active ingredient promotes at least one of transcription of a nucleic acid that suppresses mRNA expression by RNA interference and expression of Argonaute2 (Ago2).
R1、R2およびR3は、それぞれ、水素原子または疎水基であり、互いに同一でも異なっていてもよい。The accelerator according to claim 1, wherein the resveratrol and the resveratrol derivative are compounds represented by the following chemical formula (1).
R 1 , R 2 and R 3 are each a hydrogen atom or a hydrophobic group, and may be the same or different from each other.
R1、R2およびR3における前記疎水基が、それぞれ、飽和または不飽和炭化水素基であり、
前記飽和または不飽和炭化水素基は、分枝構造を含んでいても含んでいなくてもよく、環状構造を含んでいても含んでいなくてもよく、さらに、1または複数のアルコキシ基またはアリールオキシ基で置換されていても置換されていなくてもよい、
請求項2記載の促進剤。In the chemical formula (1),
The hydrophobic groups in R 1 , R 2 and R 3 are each saturated or unsaturated hydrocarbon groups;
The saturated or unsaturated hydrocarbon group may or may not contain a branched structure, may or may not contain a cyclic structure, and further contains one or more alkoxy groups or May or may not be substituted with an aryloxy group,
The accelerator according to claim 2.
前記遺伝子は、RNA干渉によりmRNAの発現が抑制される遺伝子であり、
請求項1から9のいずれか一項に記載の促進剤により、RNA干渉によりmRNAの発現を抑制する核酸の転写、およびArgonaute2(Ago2)の発現の少なくとも一方を促進させることを特徴とする治療方法。A method of treating a disease involving a specific gene,
The gene is a gene whose mRNA expression is suppressed by RNA interference,
A therapeutic method characterized by accelerating at least one of transcription of a nucleic acid that suppresses mRNA expression by RNA interference and expression of Argonaute2 (Ago2) with the promoter according to any one of claims 1 to 9. .
前記遺伝子は、RNA干渉により発現が抑制される遺伝子であり、
請求項1から9のいずれか一項に記載の促進剤と、
前記遺伝子のmRNAの発現をRNA干渉により抑制する外因性の核酸とを含み、
請求項1から9のいずれか一項に記載の促進剤が、前記外因性の核酸の転写、およびArgonaute2(Ago2)の発現の少なくとも一方を促進することを特徴とする医薬品。A drug for treating a disease involving a specific gene,
The gene is a gene whose expression is suppressed by RNA interference,
An accelerator according to any one of claims 1 to 9;
An exogenous nucleic acid that suppresses the expression of mRNA of the gene by RNA interference,
A pharmaceutical agent, wherein the promoter according to any one of claims 1 to 9 promotes at least one of transcription of the exogenous nucleic acid and expression of Argonaute2 (Ago2).
前記標的遺伝子のmRNAの発現を抑制する外因性の核酸を細胞に導入する工程を含み、
請求項1から9のいずれか一項に記載の促進剤により、前記導入された外因性の核酸の転写、およびArgonaute2(Ago2)の発現の少なくとも一方を促進させることを特徴とするノックダウン方法。A method of knocking down a target gene by RNA interference,
Introducing into the cell an exogenous nucleic acid that suppresses the expression of the mRNA of the target gene,
A knockdown method characterized by promoting at least one of transcription of the introduced exogenous nucleic acid and expression of Argonaute2 (Ago2) by the promoter according to any one of claims 1 to 9.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011218815 | 2011-10-02 | ||
JP2011218815 | 2011-10-02 | ||
PCT/JP2012/074921 WO2013051459A1 (en) | 2011-10-02 | 2012-09-27 | Promoter capable of promoting inhibition of expression of mrna by rna interference, and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2013051459A1 true JPWO2013051459A1 (en) | 2015-03-30 |
JP6155191B2 JP6155191B2 (en) | 2017-06-28 |
Family
ID=48043620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013537478A Active JP6155191B2 (en) | 2011-10-02 | 2012-09-27 | Accelerator for promoting suppression of mRNA expression by RNA interference and use thereof |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6155191B2 (en) |
WO (1) | WO2013051459A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841350B2 (en) | 2011-05-11 | 2014-09-23 | ChromaDex Inc. | Method for inducing UDP-glucuronosyltransferase activity using pterostilbene |
JP6573740B2 (en) * | 2017-09-08 | 2019-09-11 | キユーピー株式会社 | Antitumor agents, foods and drinks for cancer prevention, and expression enhancers of cancer-suppressing microRNAs |
JP6830976B2 (en) * | 2019-03-08 | 2021-02-17 | キユーピー株式会社 | MicroRNA expression enhancer and food and drink for microRNA expression enhancer |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006273834A (en) * | 2004-06-28 | 2006-10-12 | Kao Corp | Ampk activator |
JP2007126390A (en) * | 2005-11-02 | 2007-05-24 | Mercian Corp | Agent for reducing blood glucose level |
JP2009500357A (en) * | 2005-07-07 | 2009-01-08 | サートリス ファーマシューティカルズ, インコーポレイテッド | Methods and related compositions for treating or preventing obesity, insulin resistance disorders and mitochondrial related disorders |
JP2009531421A (en) * | 2006-03-28 | 2009-09-03 | カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ | Single-step microwave induction method for the preparation of substituted stilbenes and their analogs |
JP2010538077A (en) * | 2007-09-07 | 2010-12-09 | ザ ユナイテッド ステイツ オブ アメリカ、 アズ リプレゼンティッド バイ ザ セクレタリー オブ アグリカルチャー | Method to improve oxidative stress and improve working memory through pterostilbene administration |
JP2011132147A (en) * | 2009-12-22 | 2011-07-07 | Kirin Holdings Co Ltd | Neutral fat absorption inhibitor comprising concentrated red wine essence as effective ingredient |
-
2012
- 2012-09-27 JP JP2013537478A patent/JP6155191B2/en active Active
- 2012-09-27 WO PCT/JP2012/074921 patent/WO2013051459A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006273834A (en) * | 2004-06-28 | 2006-10-12 | Kao Corp | Ampk activator |
JP2009500357A (en) * | 2005-07-07 | 2009-01-08 | サートリス ファーマシューティカルズ, インコーポレイテッド | Methods and related compositions for treating or preventing obesity, insulin resistance disorders and mitochondrial related disorders |
JP2007126390A (en) * | 2005-11-02 | 2007-05-24 | Mercian Corp | Agent for reducing blood glucose level |
JP2009531421A (en) * | 2006-03-28 | 2009-09-03 | カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ | Single-step microwave induction method for the preparation of substituted stilbenes and their analogs |
JP2010538077A (en) * | 2007-09-07 | 2010-12-09 | ザ ユナイテッド ステイツ オブ アメリカ、 アズ リプレゼンティッド バイ ザ セクレタリー オブ アグリカルチャー | Method to improve oxidative stress and improve working memory through pterostilbene administration |
JP2011132147A (en) * | 2009-12-22 | 2011-07-07 | Kirin Holdings Co Ltd | Neutral fat absorption inhibitor comprising concentrated red wine essence as effective ingredient |
Non-Patent Citations (7)
Title |
---|
ANEKONDA,T.S.: "Resveratrol--a boon for treating Alzheimer's disease?", BRAIN RES REV, vol. 52, no. 2, JPN6012056155, 2006, pages 316 - 26, XP024996733, ISSN: 0003260055, DOI: 10.1016/j.brainresrev.2006.04.004 * |
BAE,S. ET AL: "Resveratrol alters microRNA expression profiles in A549 human non-small cell lung cancer cells", MOL CELLS, vol. 32, no. 3, JPN6012056149, September 2011 (2011-09-01), pages 243 - 9, XP055064683, ISSN: 0003260053, DOI: 10.1007/s10059-011-1037-z * |
DHAR,S. ET AL: "Resveratrol and prostate cancer: promising role for microRNAs", MOL NUTR FOOD RES, vol. 55, no. 8, JPN6012056145, August 2011 (2011-08-01), pages 1219 - 29, XP055064682, ISSN: 0003260052, DOI: 10.1002/mnfr.201100141 * |
J AGRIC FOOD CHEM., vol. 53(9), JPN6016006099, 2005, pages 3403 - 3407, ISSN: 0003565928 * |
MARAMBAUD,P. ET AL: "Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides", J BIOL CHEM, vol. 280, no. 45, JPN6012056159, 2005, pages 37377 - 82, XP008121218, ISSN: 0003260056, DOI: 10.1074/JBC.M508246200 * |
RIMANDO,A.M. ET AL: "Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue o", J AGRIC FOOD CHEM, vol. 50, no. 12, JPN6012056151, 2002, pages 3453 - 7, ISSN: 0003260054 * |
TILI,E. ET AL: "Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effecto", BIOCHEM PHARMACOL, vol. 80, no. 12, JPN6012056141, 2010, pages 2057 - 65, XP027456072, ISSN: 0003260051, DOI: 10.1016/j.bcp.2010.07.003 * |
Also Published As
Publication number | Publication date |
---|---|
WO2013051459A1 (en) | 2013-04-11 |
JP6155191B2 (en) | 2017-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10159670B2 (en) | Methods of diagnosing and treating motor neuron diseases and other cellular stress-related diseases | |
AU2012322788B2 (en) | Micrornas in neurodegenerative disorders | |
CN102892897B (en) | The compositions of micro-RNA expression analysis of spectrum and method for pulmonary carcinoma | |
Bertero et al. | Impact of microRNAs in the cellular response to hypoxia | |
JP2020128445A (en) | iNOS INHIBITORY COMPOSITIONS AND THEIR USE AS BREAST CANCER THERAPEUTICS | |
Li et al. | Deep sequencing analysis of small non-coding RNAs reveals the diversity of microRNAs and piRNAs in the human epididymis | |
US9163235B2 (en) | Inhibitors of the miR-15 family of micro-RNAs | |
US11542503B2 (en) | Uses for prevention or treatment of brain diseases using microRNA | |
FR2877350A1 (en) | IDENTIFICATION AND USE OF miRNAs INVOLVED IN THE DIFFERENTIATION OF CELLS FROM MYELOID LEUKEMIA | |
JP2013514089A5 (en) | ||
WO2008029790A1 (en) | Novel nucleic acid | |
TWI419898B (en) | Sense oligonucleotide having suppressing effect on inos expression and composition comprising the same | |
US20140187603A1 (en) | Microrna inhibitors comprising locked nucleotides | |
JP6155191B2 (en) | Accelerator for promoting suppression of mRNA expression by RNA interference and use thereof | |
WO2008084319A2 (en) | Novel nucleic acid | |
US20220170095A1 (en) | Method for diagnosis of alzheimer's disease using microrna | |
Willecke et al. | Cannabinoid receptor 2 signaling does not modulate atherogenesis in mice | |
Jiang et al. | β-Sitosterol regulated microRNAs in endothelial cells against an oxidized low-density lipoprotein | |
TW201120218A (en) | Composition for treating atherosclerosis, use of microRNA-195, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug | |
KR101667169B1 (en) | Agent for treating cancer | |
Murakami | Non-coding RNAs and hypertension–unveiling unexpected mechanisms of hypertension by the dark matter of the genome | |
JP2011093892A (en) | Tumor proliferation inhibitor containing cancer-inhibitive micro-rna | |
A Sanek et al. | Investigating the in vivo expression patterns of miR-7 microRNA family members in the adult mouse brain | |
EP4056205A1 (en) | Micro-rna composition functionalized for dental implants | |
WO2012145743A1 (en) | Microrna-140-5p as a tumor suppressor and sensitizing agent for chemotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150428 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160412 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160617 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160906 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161208 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20161213 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170330 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170529 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170605 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6155191 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |